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Abstract
AMBER THOMPSON BRADLEY. E3 Ligase Identified by Differential Display
(EDD) enhances cell survival and cisplatin resistance in epithelial ovarian cancer
and oral squamous cell carcinoma. (Under the direction of Scott Eblen).

EDD (E3-ubiquitin ligase identified by Differential Display) is an E3 ubiquitin
ligase that is overexpressed in ovarian cancer, but is rare in benign and
borderline tumors. EDD is also overexpressed in recurrent, platinum-resistant
ovarian cancers and is associated with a two-fold increased risk of disease
recurrence and death in ovarian cancer patients, suggesting a role in tumor
survival and/or platinum resistance. EDD knockdown by siRNA induced
apoptosis in A2780ip2, OVCAR5, and ES-2 ovarian cancer cells, correlating with
a loss of the anti-apoptotic protein Mcl-1 through a GSK-3β-independent
mechanism. Transient knockdown of EDD or Mcl-1 induced comparable levels of
apoptosis in A2780ip2 and ES-2 cells. Stable overexpression of Mcl-1 protected
cells from apoptosis following EDD knockdown, accompanied by a loss of
endogenous, but not exogenous, Mcl-1 protein, indicating that EDD may regulate
Mcl-1 synthesis. Indeed, EDD knockdown induced a 1.87-fold decrease in Mcl-1
mRNA and EDD transfection enhanced murine Mcl-1 promoter driven luciferase
expression five-fold. To separate EDD survival and potential cisplatin resistance
functions, we generated EDD shRNA stable cell lines that could survive initial
EDD knockdown and demonstrated that these cells were four- to 21-fold more

xi

sensitive to cisplatin. Moreover, transient EDD overexpression in COS-7 cells
was sufficient to promote cisplatin resistance 2.4-fold, dependent upon its E3
ligase activity. In vivo, mouse intraperitoneal ES-2 and A2780ip2 xenograft
experiments showed that mice treated with EDD siRNA by nanoliposomal
delivery (DOPC) along with cisplatin had significantly less tumor burden than
those treated with control siRNA/DOPC alone (ES-2, 77.9% reduction, p=0.004;
A2780ip2, 75.9% reduction, p=0.042) or control siRNA/DOPC with cisplatin in
ES-2 (64.4% reduction, p=0.035), with a trend in A2780ip2 (60.3% reduction,
p=0.168). These results identify EDD as a dual regulator of cell survival and
cisplatin resistance and suggest EDD is a therapeutic target for ovarian cancer.
Additionally, edd is overamplified in oral squamous cell carcinoma of the tongue.
Preliminary results in this carcinoma indicate similar roles of EDD in regulating
cellular survival and cisplatin resistance as demonstrated in ovarian cancer.
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Chapter 1
Introduction

1

Ovarian Cancer
Ovarian cancer is the leading gynecological cancer and the fifth leading
cause of cancerous deaths of females in the United States. Approximately
20,000 women each year are diagnosed with this cancer with about 14,000
women dying each year from this disease (Siegel, Naishadham et al. 2013). Most
women will die from recurrence after their tumors are drug resistant. The death
rate is high in ovarian cancer patients because symptoms are overlooked or
patients are not diagnosed until the disease has advanced. Common symptoms
such as abdominal bloating and pain are not present until the tumors have
metastasized throughout the peritoneal cavity. Current conventional treatments
include surgical debulking of the tumor or removal of the reproductive organs,
along with chemotherapy treatment such as paclitaxel, cisplatin, and/or
carboplatin.
Etiology of Epithelial Ovarian Cancer
Over 85% of ovarian tumors are epithelial carcinomas, which are thought
to arise from the ovarian surface epithelium (mesothelium) (Auersperg, Wong et
al. 2001). Tumors can also develop out of germ cells or stromal cells, which
maintain the structural integrity of the ovaries and supply hormones. The origin of
ovarian cancer has been highly debated over the past decade. Research in
patients with familial ovarian cancer, arising as a result of mutations in BRCA1,
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BRCA2, or p53, has indicated that these cancers may originate from the fallopian
tubes (Selvaggi 2000, Powell, Kenley et al. 2005, Medeiros, Muto et al. 2006,
Lee, Miron et al. 2007, Mehrad, Ning et al. 2010, Kurman and Shih Ie 2011).
More recent research has also linked the fallopian tubes to the origin of ovarian
cancer in non-hereditary cases (Lee, Miron et al. 2007, Mehrad, Ning et al. 2010,
Kurman and Shih Ie 2011). Most epithelial ovarian tumor cells resemble cells
from the fimbria, the distal part of the fallopian tube. It is difficult to determine the
etiology of ovarian carcinoma because patients are not usually diagnosed until
they exhibit advanced stages of the disease. This is a result of the dismissal of
common symptoms of ovarian cancer such as abdominal pressure, bloating,
pelvic pain, nausea, constipation, loss of appetite, and loss of energy. These
symptoms are vague and often associated with more common issues such as
digestive problems, leading to their dismissal as symptoms of ovarian cancer.
Left untreated, ovarian cancer typically spreads locally to the opposite ovary,
uterus, and the intraperitoneal cavity. While rare, metastasis to the liver, adrenal
glands, spleen, and lungs may occur in the most aggressive forms of cancer. The
most prevalent form of ovarian cancer is serous epithelial cancer (Seidman,
Horkayne-Szakaly et al. 2004). It is commonly believed now that serous ovarian
cancer originates from the fallopian tube. Other epithelial ovarian carcinomas can
be classified as mucinous, endometrioid, clear cell, transitional cell (Brenner
type), squamous, and mixed epithelial.

3

Risk Factors
The most common risk factors for ovarian cancer are heredity. Other risk
factors include hormonal and environmental sources. The tumor protein 53 (p53)
is commonly mutated in many types of cancers, including ovarian cancer. The
tumor suppressor p53 activates DNA damage repair when damage is sensed,
resulting in cell cycle arrest until the damage is repaired and apoptosis if the
damage is irreparable. Alterations in p53 exist in 96% of high grade ovarian
serous carcinomas, the most common subtype of ovarian cancer, but are rare in
low grade serous carcinomas (Green, Berns et al. 2006). Human epidermal
growth factor receptor 2 (HER2) is overexpressed in many types of cancers as
well and is associated with a poor prognosis in these patients. HER2 is a
receptor in the ErbB family of receptors and this protein regulates the signaling
pathways linked to promoting cell proliferation and prevention of apoptosis.
Overexpression of HER2 is estimated to be present in 10% of ovarian cancers
(Verri, Guglielmini et al. 2005). Mutations in BRCA1 and BRCA2 in patients
indicate a 30% to 70% chance of developing ovarian cancer by the age of 70
(Antoniou, Pharoah et al. 2003, Chen and Parmigiani 2007). BRCA proteins are
involved in mismatch repair mechanisms to repair DNA damage in the double
helix such as during homologous recombination. Alterations in the cyclin kinase
inhibitors p21 and p27, and the cell cycle protein cyclin E (Bali, O'Brien et al.
2004, Schmider-Ross, Pirsig et al. 2006, Nakayama, Nakayama et al. 2010) are
also present in ovarian tumors. Alterations in other signaling pathways can also
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occur as a result of mutations in KRAS (Vereczkey, Serester et al. 2011) and PI3
kinase (p110 subunit) (Levine, Bogomolniy et al. 2005).
Other risk factors related to the development of ovarian cancer include
environmental and hormonal factors. These risks are related to the commonly
believed predisposition to ovarian cancer – ovulation (Fathalla 1971). It has been
a long held belief that ovarian cancer arises as a result of the disruption and
repair of the epithelial cells in the ovary due to ovulation and the oocyte leaving
the ruptured follicle. Supporting this theory, pregnancy and the use of oral
contraceptives to regulate the ovulation cycle are well known to reduce the risks
of developing ovarian cancer. Ovarian cancer typically affects menopausal and
post-menopausal women. Infertility has been shown to increase the risk of
ovarian cancer, but it is unclear whether this is due to the lack of pregnancy or
the use of fertility drugs which promotes this effect. Since hormones control the
ovulation cycle, gonadotropins (Cramer and Welch 1983), which stimulate the
ovarian epithelium, and estrogens and androgens, which promote reproductive
capabilities, are known to promote carcinogenesis (Parazzini, La Vecchia et al.
1994, Karlan, Jones et al. 1995, Rodriguez, Calle et al. 1995, Silva, Tornos et al.
1997). In the 1960s, an association was found between the use of talcum powder
and an increased risk of ovarian cancer, which suggests that toxins can enter the
genital track and migrate upward to the reproductive organs (Henderson,
Hamilton et al. 1979, Harlow, Cramer et al. 1992, Huncharek, Geschwind et al.
2003).
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Treatment of Ovarian Cancer
Standard treatment of ovarian cancer is a combination of cytoreductive
surgery and chemotherapies such as taxane (paclitaxel) and platinum (cisplatin
or carboplatin) drugs. These treatments have been the standard of care for
ovarian cancer patients for the last few decades, indicating a need for updated
strategies. Surgical cytoreduction may include a total hysterectomy, bilateral
salpingo-oophoectomy (removal of the ovaries and fallopian tubes), removal of
pelvic or para-aortic lymph nodes, and/or omentectomy (removal of the
abdominal lining) (Kim, Ueda et al. 2012). Clear cell carcinomas are notoriously
resistant to paclitaxel and carboplatin, so these tumors are typically treated with
irinotecan and cisplatin. Chemotherapies that are under investigation are PARP
inhibitors and bevacizumab, an antibody directed against vascular endothelial
growth factor (VEGF). PARP inhibitors show promising results in patients with
BRCA mutations, since both PARP and BRCA are involved in DNA damage
repair.
Following drug activation by aqueous hydrolysis, cisplatin and carboplatin
exert their activity through interaction with DNA, RNA, and protein with a
cytotoxic effect mediated through the formation of interstrand and intrastand
crosslinks in DNA, creating DNA adducts. This elicits a DNA damage response in
the cell, where nucleotide excision repair and mismatch repair are able to repair
the damage. If the damage is not repaired, then the DNA damage signals for
apoptosis to occur. Cisplatin (cis-diammine dichloroplatinum (II)) was first
discovered in 1965 as an inhibitor of proliferation by Rosenberg and colleagues
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when studying Escherichia coli exposed to a current delivered by platinum
electrodes (Rosenberg, Vancamp et al. 1965). It was discovered that a platinum
complex, specifically the cis isomer, inhibited binary fusion in the bacteria.
Carboplatin (cis-diammine (1,1-cyclobutanedicarboxylate) platinum (II)) was
created as an analog to cisplatin to reduce severe side effects, such as
nephrotoxicity (kidney damage), neurotoxicity (nerve damage), and ototoxicity
(hearing loss). In clinical trials, carboplatin has the same efficacy as cisplatin in
ovarian cancer, although cisplatin is still more effective in other types of cancer,
such as head and neck cancer. Paclitaxel was first discovered and isolated from
the bark of the Pacific yew tree (Taxus brevifolia) in 1967 (Wani, Taylor et al.
1971). Paclitaxel exerts its effect through the stabilization of microtubules to
ultimately prevent breakdown of microtubules during mitosis.
Recurrent Ovarian Cancer
The five year survival rate of ovarian cancer patients is low (35%) after
treatment with surgical debulking and chemotherapy treatment (paclitaxel,
carboplatin, and/or cisplatin) (Green, Berns et al. 2006). Initial response rates to
surgery and chemotherapy is 70%-80% in ovarian cancer patients (du Bois, Luck
et al. 2003, Ozols, Bundy et al. 2003). However, most patients will eventually
relapse with a poor prognosis and progression-free survival time of only 18
months in those with advanced disease (McGuire, Hoskins et al. 1996, Rubin,
Randall et al. 1999). There are a multitude of proposed mechanisms of
resistance to both platinum drugs and paclitaxel. Many mechanisms overlap as
major mechanisms of resistance to various chemotherapeutic drugs (Siddik
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2003). Table 1.1 contains a list of identified mechanisms of resistance to the
platinum drugs and paclitaxel, although this table provides a selective number of
mechanisms and is not meant to be an exhaustive description of mechanisms of
resistance to these chemotherapies. Most methods of resistance are relevant to
the mechanism of action of each drug, as described above, or its presence in the
cell. Obviously, it is extremely difficult to target the potential cellular methods of
resistance to these drugs, indicating the need for better therapeutics and/or
chemotherapeutic drug combinations in an effort to decrease multidrug
resistance in tumors.
Table 1.1
General Mechanisms of Resistance to Platinum Chemotherapy or Paclitaxel
Resistance Mechanisms to Platinum
Drugs

Resistance Mechanisms to Paclitaxel

Increased Efflux Drug Transporters (ABC, MDR transporters)
Decreased Uptake Drug Transporters
Loss of p53 Function
Downregulation of Pro-apoptotic proteins (Bax, Bad)
Upregulation of Anti-apoptotic proteins (Bcl-2, Bcl-XL, Mcl-2)
Increased Drug Inactivation
(Glutathione and metallothioneins)
Increased DNA damage repair
Modifications of Tubulin
Increased MAPK pathway
Delay in mitotic entry
Ras mutation or overexpression
HER2 overexpression
Increased PI3K/Akt pathway

MAP Kinase Signaling in Ovarian Cancer
Activating mutations of BRAF and KRAS are prevalent in low grade and
borderline ovarian tumors (approximately 60%), but is rarely observed in high
grade serous ovarian carcinomas (Singer, Oldt et al. 2003). These mutations are
mutually exclusive. This indicates that activation of signaling through RAF and
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RAS are important in the development of ovarian tumors. Downstream of RAF
and RAS, the activation of the MAP (mitogen-activated protein) kinase pathway
has been detected in 80% of low grade ovarian tumors and 40% of high grade
tumors (Hsu, Bristow et al. 2004). The MAPK pathway is critical for the
transmission of extracellular signals, such as a response to the presence of
growth factors, stress, and cytokines, to intracellular signaling pathways.
Activation of the MAPK pathway leads to the activation of protein kinases,
transcription factors, and other nuclear proteins which can lead to extensive
proliferation

and

evasion

of

apoptosis,

promoting

tumor

development.

Constitutive activation of the MAPK pathway also leads to alterations in other
pathways, such as the Akt pathway, which also participates in the development
of tumors.
The MAPK pathway includes three major pathways which are differentially
regulated by extracellular signals and thus lead to unique intracellular signaling
processes. This is illustrated in Figure 1.1 which depicts an extremely simplified
view of MAPK signaling pathways. There are many other upstream and
downstream proteins involved in each signaling cascade as well as considerable
crosstalk between these pathways and other pathways not included in this figure.

Figure 1.1. MAP Kinase Signaling Pathways
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Oral Squamous Cell Carcinoma
Approximately 41,380 Americans each year are diagnosed with cancers of
the oral cavity or pharynx, affecting more males (29,620) than females (11,760)
(Siegel, Naishadham et al. 2013). Almost 20% of Americans that are diagnosed
with carcinoma affecting these tissues will die from this disease each year.
Worldwide, cancers of the oral cavity and pharynx affect 337,931 people each
year, with a rate of mortality of approximately 54% (Parkin, Bray et al. 2005).
The five year survival in the United States has increased to about 65%
(increased from 53% in the 1970s) (Siegel, Naishadham et al. 2013). In contrast,
the five year survival in developing countries for these patients is only about 31%
(Parkin, Bray et al. 2005). Diagnosis typically occurs in patients 50 years old or
older.
Etiology
Squamous cell carcinomas of the oral cavity can affect the tongue, base of
the tongue, tonsils, nasopharynx, pharynx, and larynx (Saba, Goodman et al.
2011). Each of these carcinomas is distinct. This type of carcinoma affects
squamous cells, a type of epithelial cell. Molecular changes in these cells leading
to carcinoma include gene amplification or overexpression of oncogenes such as
erbB2, epidermal growth factor receptor (EGFR), myc, and cyclin D1or mutations
in tumor suppressors such as p53 or p16 (Mehrotra and Yadav 2006).
Risk Factors
The high prevalence of oral cancer around the world, especially in
developing countries, is due to increased use of tobacco (either chewing or
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smoking) and alcohol use, the primary causes of oral cancer. Viral infection with
Human papillomavirus (HPV), commonly HPV 16 or HPV 18, also increases the
risk of oral cancer while infection with Epstein-Barr virus has been linked to
cancers of the nasopharynx (Parkin, Bray et al. 2005). Often HPV infection
occurs as a result of oral-genital contact. Tumors linked to these viruses are
often easier to treat allowing for increased survival in these patients (Ang, Harris
et al. 2010). Typically, cancers of the tongue are not related to HPV infection, but
rather to tobacco and alcohol use. Radiation exposure and immune deficiency
have also been implicated in the development of these carcinomas.
Treatment of Oral Squamous Cell Carcinoma
Initially most oral carcinomas are asymptomatic often leading to a late
diagnosis. Oral screenings from a dentist are critical to the diagnosis of this
disease before progression and metastasis occurs. Treatments for oral
squamous cell carcinomas of the various oral regions include surgical removal of
the tumor(s), radiation, and chemotherapies such as cisplatin, paclitaxel, and 5fluorouracil. Surgery and radiation are first line treatments with chemotherapy
being used as an adjuvant therapy in patients with metastasis. Metastasis to the
lymph nodes makes treatment much more difficult and decreases survival in
these patients.
Mechanisms of Resistance
As with other cancers, resistance to chemotherapy treatment is a common
problem in oral squamous cell carcinoma, exacerbated by the fact that
chemotherapy is typically not used as an intervention until the disease has
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progressed to the lymph nodes. Cancers affecting the oral cavity are unique in
that the environment of the oral cavity has increased acidity. This increased
acidity can affect the absorption of chemotherapeutic agents in these tumor cells
(Griffiths 1991). This unique environment is thought to be maintained by vacuolar
ATPases in these epithelial cells (Newell, Franchi et al. 1993, Yamagata, Hasuda
et al. 1998). Other causes of drug resistance in these cells are common causes
such as the overexpression of multi-drug resistance proteins to export drug out of
the cell before allowing a cellular effect, as well as effects on the cell cycle,
apoptosis, drug inactivation, and alterations in critical cellular pathways such as
ERK, Akt, and p53. These common resistance mechanisms are described in
more detail in the previous section on mechanisms of resistance in ovarian
cancer.
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Ubiquitin/Proteasome Pathway
History
The Nobel Prize in chemistry was awarded to Avram Hershko, Aaron
Ciechanover, and Irwin Rose in 2004 for their work in the late 1970s to early
1980s discovering the degradation of proteins by ubiquitination. Hershko and
colleges used fractionation of cellular components of reticulocytes to purify and
identify proteins involved in ATP dependent protein degradation (Ciechanover,
Heller et al. 1980, Hershko, Ciechanover et al. 1980, Hershko, Eytan et al. 1982,
Hershko, Heller et al. 1983, Ciechanover, Hod et al. 2012).
Ubiquitin
The 76 amino acid polypeptide ubiquitin is expressed in all eukaryotes and
is highly conserved. Ubiquitin is encoded by multiple genes, often as an
oligomer, and processed to monomeric forms in order to be activated and
covalently linked to proteins. The addition of ubiquitin to proteins is generally
associated with protein degradation by the 26S proteasome (Hough, Pratt et al.
1986); however, dependent on the type of ubiquitin attachment, this may not
always be the case. When a protein is labeled with a multi-ubiquitin chain by
isopeptide bonds on Lys 6 (Nishikawa, Ooka et al. 2004), Lys 11, Lys 27, Lys 29
(Chastagner, Israel et al. 2006), Lys 33 (Al-Hakim, Zagorska et al. 2008), or Lys
63 (Deng, Wang et al. 2000, Wang, Deng et al. 2001, Herman-Bachinsky, Ryoo
et al. 2007) of ubiquitin, this can regulate cellular activities independent of protein
degradation, but these ubiquitin modifications can also signal for proteolysis. The
initial ubiquitin is added to either the ε-amino group of lysine or the amino
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terminal residue in the targeted protein (Ciechanover and Ben-Saadon 2004).
Addition of a multi-ubiquitin chain on Lys 48 on ubiquitin is the prototypical
ubiquitin modification on a protein to designate its degradation by the 26S
proteasome. Monoubiquitination of proteins can regulate cellular functions or
localization of the ubiquitylated protein (Levkowitz, Waterman et al. 1999,
Mukhopadhyay and Riezman 2007). Ubiquitin-mediated cellular activities,
independent of the proteasome, include kinase activation, transcription factor
activation, protein translocation, endocytosis, lysosomal targeting, and DNA
damage repair.
Ubiquitination
Ubiquitin activating E1 enzymes begin the ubiquitination pathway by
binding to both MgATP and ubiquitin in order to form an activated ubiquitin
adenylate (Haas and Rose 1982, Hershko, Heller et al. 1983). Then E1 protein
can form a thiol-ester bond between a critical cysteine amino acid in E1 and the
carboxyl-terminal glycine amino acid of ubiquitin. E1 is able to carry two
ubiquitins, an ubiquitin adenylate and an ubiquitin linked by a thiol-ester bond to
E1. E1 transfers the ubiquitin to an ubiquitin conjugating E2 enzyme, mediated
through a cysteine in the active site of an E2, through transesterification. Then
E2 either transfers the ubiquitin directly to the conserved, critical cysteine residue
in the HECT domain of HECT family E3 ubiquitin ligases or forms an isopeptide
bond between the glycine in ubiquitin and an internal lysine residue on the
substrate protein or a growing ubiquitin chain on the substrate protein. This
general process is illustrated in Figure 1.2. As E3 ubiquitin ligases provide
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specificity in the ubiquitination process, more than 600 genes encode E3 ligases
whereas about 40 genes are used to encode E2 enzymes (Deshaies and
Joazeiro 2009). While there are some E3-E2 combinations that are restricted,
most E3 ligases can interact with multiple E2 enzymes. Some combinations also
include a multi-subunit complex of E3 ligases, such as the SCF (Skp, Cullin, Fbox containing complex) or APC (Anaphase Promoting Complex), each of which
can include several individual ubiquitin ligases in a complex.
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Figure 1.2. Ubiquitination
Adapted from: (Fang and Weissman 2004) and (Eldridge and O'Brien
2010)
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E3 Ubiquitin Ligases
E3 ubiquitin ligases complete the ubiquitination process by attaching
either monomeric ubiquitin or a multi-ubiquitin chain to specific target proteins.
There are several different domains of E3 ubiquitin ligases, which are unique to
ubiquitin ligases of different families. These distinctive domains include HECT
(Homologous to E6-AP Carboxyl Terminus), RING (Really Interesting New
Gene), U-box, PHD (Plant Homeo-Domain), and LAP (Leukemia-Associated
Protein) domains, which are all critical in mediating the transfer of ubiquitin to
protein substrates. The different families of E3 ubiquitin ligases and their
distinctive features are summarized in Figure 1.3. HECT domain-containing E3
ubiquitin ligases include a critical cysteine amino acid about 35 amino acids from
the carboxy-terminus in their HECT domain of about 350 amino acids, which
allows for ubiquitin to be transferred directly onto the E3 ligase before
ubiquitination of the substrate occurs (Huibregtse, Scheffner et al. 1995). This
also permits HECT E3 ligases to ubiquitinate themselves. The RING finger
domain is designated by the presence of eight conserved cysteine and histidine
amino acids which utilize two zinc ions to transfer ubiquitin onto a substrate. This
domain is defined as Cys-X2-Cys-X(9-39)-Cys-X(1-3)-His-X(2-3)-Cys-X2-Cys-X(4-48)Cys-X2-Cys, in which X is defined as any amino acid (Borden and Freemont
1996). The PHD finger is similar to the RING finger motif, but has a histidine in
the fourth position rather than a cysteine (Capili, Schultz et al. 2001).
E3 ubiquitin ligases are notoriously large proteins with multiple domains
allowing for protein-protein interactions, which permit the interaction with
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potential ubiquitination targets. Unlike kinases, which have a catalytic binding
pocket that is critical for the binding of ATP, an active site in a binding pocket is
not present in E3 ubiquitin ligases. This makes the discovery of E3 ubiquitin
ligase small molecule inhibitors extremely difficult. While targeting the
protein/protein and protein/ubiquitin interaction domains may seem relevant, the
promiscuity of ubiquitin ligases to interact with multiple E2 enzymes and
substrates makes this a difficult proposition. Nutlin-3, a cis-imidazoline analog,
binds to the E3 ubiquitin ligase Mdm2 to prevent its interaction with the tumor
suppressor p53. The inhibition of this interaction leads to the accumulation of p53
to promote apoptosis (Vassilev, Vu et al. 2004). Clinical trials have not been
completed on this inhibitor and the effects of this inhibitor on normal cells has yet
to be determined (Secchiero, Bosco et al. 2011).
E3 enzymes are the ultimate determining factor for substrate specificity in
the ubiquitination process (Hershko, Heller et al. 1986). Specificity is also
conferred by the type of the ubiquitin attachment, including which lysine in the
protein is targeted for ubiquitination, the type of isopeptide linkage (such as Lys
6, Lys 48, Lys 63, etc.), the addition of one ubiquitin protein, or the addition of a
multi-ubiquitin chain.
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Figure 1.3. E3 Ubiquitin Ligases
From (Hatakeyama and Nakayama 2003)
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26S proteasome
The 26S proteasome consists of a 20S proteasome in its catalytic core
and two 19S caps on either end of the catalytic core (Arrigo, Tanaka et al. 1988,
Hoffman, Pratt et al. 1992). The 19S cap, also known as PA700, recognizes
ubiquitinated proteins that have been targeted for degradation. Ubiquitin is
removed and recycled before proteins enter the proteolytic core of proteasomes.
The 20S proteasome utilizes ATP to degrade folded proteins, unfolded proteins,
and peptides. In order to prevent random degradation of proteins in the cell, the
catalytic core is insulated by the two 19S caps on either end of the channel
formed by the proteasome core (Glickman, Rubin et al. 1998).
The 19S caps are made up of several different subunits to provide the
complex with a range of activities including deubiquitination, recognition of
ubiquitin, ATPase, and reverse chaperone activity to allow target proteins to be
unfolded and funneled into the proteasome pore. The 19S cap is composed of
nine subunits in its base complex and eight subunits in its lid complex (Fang and
Weissman 2004). The 20S proteasome core is comprised of four stacked rings
with seven subunits, each ring made of either α type or β subunits (αββα). The
rings composed of β subunits are dependent on the formation of the α subunit
ring first. The two inner-most rings are composed of β subunits, which possess
catalytic activity. The β subunits have a critical threonine amino acid at the amino
terminus of the protein, which is exposed after a pro-sequence is cleaved off the
protein. The exposed threonine acts as a nucleophile to cleave peptides
(Kisselev, Songyang et al. 2000). Different types of protease activity (trypsin-like,

21

chymotrypsin-like, and caspase-like) are dependent of different types of β
subunits (Heinemeyer, Fischer et al. 1997, Jager, Groll et al. 1999). The
proteasome will cleave proteins until the peptides that remain are small enough
to diffuse out of the proteasome.
Most protease inhibitors are peptides which mimic the transition state of a
peptide undergoing proteolysis, but in this case the peptide is unable to be
cleaved. These inhibitors can either reversibly or irreversibly inhibit the
proteasome, dependent on a covalent bond forming between the peptide inhibitor
and the proteasome. For example, MG132 is a reversible proteasome inhibitor
with the peptide sequence Z-Leu-Leu-Leu-CHO, which is a peptide aldehyde.
Most proteasome inhibitors form a hemiacetyl complex with the critical threonine
of the β subunits (Rock, Gramm et al. 1994).
Deubiquitinating Enzymes
Deubiquitinating enzymes include ubiquitin carboxy-terminal hydrolases
(UBHs) and ubiquitin-specific processing proteases (UBPs).

UBPs generally

remove ubiquitin from proteins with a multi-ubiquitin chain. UBHs are generally
associated with generating free monomeric ubiquitins, either from a multiubiquitin chain on targeted proteins or from ubiquitin genes that are translated
into a poly-ubiquitin chain (Kim, Park et al. 2003). There are approximately 79
deubiquitinating enzymes, each with specificity (Nijman, Luna-Vargas et al.
2005). The removal of ubiquitins can prevent a protein from being degraded.
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EDD
EDD was initially discovered in humans as a progestin-regulated HECT
family E3 ubiquitin ligase that was identified by differential display in T47D breast
cancer cells (Callaghan, Russell et al. 1998). Thus, EDD is an abbreviation for
E3 ubiquitin ligase identified by Differential Display. Other names for EDD include
hyd (hyperplastic discs gene) and ubr5 (ubiquitin protein ligase E3 component Nrecognin 5). The first ortholog of this gene was discovered in Drosophila
melanogaster as the hyperplastic discs’ tumor suppressor gene (Mansfield,
Hersperger et al. 1994). In Drosophila melanogaster, EDD crucially regulates
proliferation and differentiation via the hedgehog and decapentaplegic signaling
pathways. EDD has also been identified in rat testis during postnatal
development and was characterized as Rat100 (Oughtred, Bedard et al. 2002).
In rat testis, mutants of the edd gene cause defects in spermatogenesis. EDD is
ubiquitously expressed in humans with the highest levels present in testis, brain,
pituitary, and kidney. Significant levels of EDD expression were also detected in
the uterus, placenta, stomach, and prostate (Callaghan, Russell et al. 1998).
The edd gene is located on chromosome 8q22.3 (Callaghan, Russell et al.
1998). The EDD protein is over 300 kDa in size and encodes several functional
domains which are depicted in Figure 1.4. EDD contains two nuclear localization
signals, a Poly A Binding Protein homology domain, two regions for proteinprotein interactions (UBA, UBR), several potential steroid receptor binding motifs
(indicated by * in Figure 1.4), and a HECT domain with a conserved cysteine
residue, which is critical for the transfer of ubiquitin onto EDD and subsequently
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onto a target protein. The resolved structure of the HECT domain of EDD is
depicted in Figure 1.5. The structure of the UBA domain of EDD is illustrated in
Figure 1.6. EDD interacts with importin α5 to transport EDD into the nucleus
(Henderson, Russell et al. 2002). This interaction occurs at EDD’s nuclear
localization sequences, one of which is simple and the other bipartite.

24

Figure 1.4. Domains of EDD from (Henderson, Russell et al. 2002)

Figure 1.5. C-Terminal HECT Domain of EDD from (Matta-Camacho, Kozlov et
al. 2012)

Figure 1.6. UBA domain of EDD from (Kozlov, Nguyen et al. 2007)
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My mentor, Dr. Scott Eblen, discovered that EDD is a direct substrate of
ERK2 (Eblen,
Eblen, Kumar et al. 2003
2003).. Our lab has determined several sites of
phosphorylation on EDD
EDD, which is depicted in Figure 1.7. Kinases, other than
ERK2, that phosphorylate EDD are still unknown at this time.

Figure 1.7. Phosphorylation sites of EDD from (Bethard,
Bethard, Zheng et al. 2011)
2011

EDD has multiple functions in the cell, which can be dependent or
independent on its ubiquitin ligase activity (Figure 1.9). One of EDD’s
ubiquitination targets is poly A binding protein interacting protein 2 (Paip2), an
inhibitor of PABP activity. EDD targets Paip2 for degradation, which increases
overall translation by increasing the activity of PABP (Yoshida,
Yoshida, Yoshida et al.
2006). Another interaction which permits EDD to affect translation is an
interaction with α4
4 phosphoprotei
phosphoprotein,
n, which is a component of the mTOR
(mammalian target of rapamycin) pathway, promoting translational initiation
(McDonald,
McDonald, Sangster et al. 2010
2010).. This interaction occurs through the PABP-C
PABP
domain of EDD. The α4
4 phosphoprotein can also interact with PABP itself.
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β-catenin is the first protein that has been shown to be ubiquitinated by
EDD, but not degraded as a consequence. EDD ubiquitinates β-catenin to
increase its stability with ubiquitin chains linked by lysine residues 29 and 11
(Hay-Koren, Caspi et al. 2011). This allows for an increase in transcription of
Wnt-regulated and β-catenin regulated genes. Many of these genes are linked
with the progression of cancer and poor prognosis in cancer patients. However,
EDD was identified as an interacting partner of adenomatous polyposis coli
(APC), which allows for the stabilization of APC to enhance its protein expression
(Ohshima, Ohta et al. 2007). This also promotes the inhibition of β-catenin, a
downstream target of APC, which suggests that EDD may have a role as a tumor
suppressor in colorectal cancer, where alterations in APC are prevalent.
Another ubiquitination target of EDD is DNA Topoisomerase II-binding
protein (TopBP1). In cells without DNA damage, EDD mediates the ubiquitination
and subsequent degradation of TopBP1 (Honda, Tojo et al. 2002). In response to
DNA damage, TopBP1 is protected from ubiquitination due to phosphorylation to
promote its co-localization with γ-H2AX at sites of DNA damage. TopBP1 is then
able to protect the ends of the damaged DNA and facilitate their repair. Thus,
EDD manages TopBP1 protein levels to coordinate DNA damage response.
EDD also interacts with several proteins to modulate their activity.
Henderson et al. reported an interaction between EDD and CHK2, a DNA
damage checkpoint kinase (Henderson, Munoz et al. 2006). This interaction is
required for the phosphorylation of CHK2 on threonine 68 and the resulting
activation of CHK2 as a result of DNA damage detection. The CHK2 kinase
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phosphorylates proteins in cells with damaged DNA to promote mitotic arrest,
DNA damage repair, and apoptosis if the damage is irreparable (Bartek, Falck et
al. 2001, Falck, Mailand et al. 2001, Stevens, Smith et al. 2003). EDD is critical to
this response. Knockdown of EDD in cells prevents DNA damage response and
CHK2 activation. Similarly, the depletion of EDD in cells leads to defective DNA
damage checkpoint activation resulting in mitotic catastrophe. Loss of EDD
increased protein expression of E2F1 and Cdc25A/C, while decreasing
expression of p27 and p21, with or without the presence of DNA damage
(Munoz, Saunders et al. 2007). The disruption of these cell cycle checkpoints
leads to premature mitosis in the presence of DNA damage, buildup of polyploid
cells, and ensuing apoptosis. Other indications that EDD is involved in regulating
DNA include its interaction with CIB1, a DNA-dependent kinase-interacting
protein, and interaction with PMS1 and PMS2 during mismatch repair
(Henderson, Russell et al. 2002, Cannavo, Gerrits et al. 2007). Furthermore,
EDD ubiquitinates TopBP1 (topoisomerase IIβ-binding protein) as mentioned
above.
In addition to EDD’s role in the DNA damage pathway, EDD was recently
shown to cooperate with TRIP12, another E3 ubiquitin ligase, to control
accumulation of RNF168 (Gudjonsson, Altmeyer et al. 2012). RNF168 is a critical
component of a complex to promote the ubiquitination of histones as a response
mechanism to DNA damage. The presence of EDD and TRIP12 are crucial to
maintain RNF168 levels to prevent extensive chromatin ubiquitination from
spreading to undamaged chromosomes. Confirming the results of this study,
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Okamoto et al. then demonstrated that inhibition of RNF168 by EDD is able to
impede chromosome end-to-end fusions (Okamoto, Bartocci et al. 2013). This
ultimately allows for a complex including TRF2 to protect chromosome ends.
These studies confirm a role for EDD is maintaining chromosome integrity.
EDD interacts with a dual specificity tyrosine phosphorylation regulated
kinase, DYRK2. DYRK2 acts as a scaffold for EDD, VPRBP, and DDB1 proteins
in an E3 ubiquitin ligase complex (Maddika and Chen 2009). The interaction of
these proteins, facilitated by DYRK2, mediates the phosphorylation and
degradation of katanin p60. EDD is the catalytic E3 ubiquitin ligase to regulate
the ubiquitination of katanin p60. Katanin p60 is a microtubule-severing agent,
which is critical during anaphase of mitosis to allow for segregation of
chromatids. If ubiquitination of katanin p60 is prevented, cells become polyploid.
Additionally, through interaction with DYRK2, EDD promotes the ubiquitination
and degradation of TERT, a catalytic subunit of telomerase (Jung, Wang et al.
2013). Phosphorylation of TERT by DYRK2 during the G2/M phase of the cell
cycle prompts interaction and ubiquitination from EDD leading to TERT
degradation. Since TERT is a subunit of telomerase, this causes inhibition of
telomerase.
There have been conflicting reports regarding an interaction between EDD
and the tumor suppressor protein p53. Research by Ling and Lin suggests that
EDD prevents ATM (ataxia telangiectasia mutated) mediated phosphorylation of
p53 on serine 15 (Ling and Lin 2011). The phosphorylation of p53 on this residue
by ATM is required for activation of p53 regulated genes in response to DNA
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damage. EDD silencing prompts p53 phosphorylation to activate p53 target
genes even in the absence of DNA damage. This results in a decrease in cells
entering S-phase. Previously, Munoz et al. demonstrated opposite results in their
research indicating that depletion of EDD leads to an increase in the percentage
of cells entering S-phase as well as opposite effects on p21 expression levels
(Munoz, Saunders et al. 2007). Also, Saunders et al. showed that the phenotype
in an EDD knockout mouse is not dependent on p53 expression, as shown in a
p53 null mouse (Saunders, Hird et al. 2004). It was proposed that the differing
conclusions from the two labs mentioned above are dependent on the cell types
used in the experiments (Watts and Saunders 2011).
EDD interacts with Ago1, Ago2, GSPT1/2, ATXN2, and DDX6 proteins in
the Argonaute-miRNA complex through its PABP-C domain (Su, Meng et al.
2011). Su et al. demonstrated that EDD is required for miRNA mediated silencing
of genes through this interaction in mouse embryonic stem cells. This interaction
is independent of ubiquitin ligase activity. MicroRNAs bind to partially
complementary mRNAs to promote mRNA degradation and prevention of
translation in targeted mRNAs.
Through mass spectroscopic analysis, EDD was identified as a part of the
HPV-18 (human papillomavirus) E6/E6AP complex, which is responsible for
ubiquitination of substrates to target them for degradation (Tomaic, Pim et al.
2011). Loss of EDD in this complex stimulates the activity of the complex to
increase proteolysis while higher EDD levels provide protection for the targeted
substrates. Tomaić et al. proposed that the alternations in EDD levels may occur
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due to progression through the viral life cycle to allow for degradation of assorted
protein substrates. This indicates a role for EDD in HPV driven malignancies.
Another study indicating a role for EDD in the regulation of the progression of
cancer found that the edd gene was upregulated after a second exposure of
ultraviolet radiation in human keratinocytes (Gupta, Chakrobarty et al. 2006). The
edd gene was subsequently downregulated in colony forming cells which were
exposed to ultraviolet radiation multiple times. The mechanism behind this
phenomenon was not elucidated.
As detailed above, EDD has many cellular functions dependent on protein
interactions and ubiquitination of target proteins (Figure 1.8). On a physiological
level, EDD is highly associated with vascularization and the function of the
protein myocardin. Edd knockout mice embryos (embryonic day 8.5-10.5)
demonstrated an inability to develop the yolk sac and allantoic vasculature
(Saunders, Hird et al. 2004). The defective development of the extra-embryonic
environment resulted in lack of proliferation and increased apoptosis. While the
knockdown of edd results in embryonic lethality, heterozygous mice developed
normally and were able to produce offspring. EDD was also identified as an
interacting partner for the transcription factor myocardin (Hu, Wang et al. 2010).
EDD cooperates with myocardin to promote its stabilization and to induce
expression of genes to regulate the differentiation of smooth muscle cells.
Recently, a chromatin binding profiling experiment identified that EDD regulates
the expression of ACVRL1, a regulator of angiogenesis (Chen, Yang et al. 2013).
ACVRL1 is a serine/threonine protein kinase that responds to the TGF-β ligand.
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The transcriptional regulation at the ACVRL1 promoter by EDD is required for
blood vessel development and motility of endothelial cells during angiogenesis.
This regulation of transcription is independent of EDD’s ubiquitin ligase activity.
Interaction with the progesterone receptor allows EDD to potentiate
expression of progestin-induced genes (Henderson, Russell et al. 2002). EDD
also serves as a coactivator for vitamin D receptor-mediated transcription. EDD’s
ability to act as a transcriptional coactivator for specific hormone receptors is
independent of its ubiquitin ligase function. Since EDD is a progestin-regulated
gene itself, this grants the opportunity for a positive feedback loop.
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Figure 1.8. Cellular Functions of EDD

Figure 1.9. Separate Roles of EDD – Dependent or Independent of Ubiquitin
Ligase Function (Modified from (Henderson, Russell et al. 2002))
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EDD in Cancer
Truncation mutants of EDD are frequently found in gastric and colorectal
cancers (Mori, Sato et al. 2002). The gene locus of edd is overamplified in
several cancers including ovarian, breast, hepatocellular carcinoma, and
metastatic melanoma (Fuja, Lin et al. 2004). Another study by Clancy et al. also
demonstrated that EDD is overexpressed in ovarian and breast cancers (Clancy,
Henderson et al. 2003). Clancy et al. analyzed several different cancers for allelic
imbalance of EDD and found that 42% of all cancers in the study had either
allelic gain or loss of the edd gene. While edd overexpression is rare in benign
and borderline ovarian cancers, 47% of all types of this cancer overexpress edd,
with 73% of serous ovarian cancers, the most prevalent form of ovarian cancer,
overexpressing edd. This information is depicted in Figure 1.10. Edd is also
overexpressed in oral squamous cell carcinoma (50%), hepatocellular carcinoma
(46%), breast cancer (31%), and metastatic melanoma (18%). In ovarian cancer,
EDD mRNA levels are often upregulated or downregulated as well, as
demonstrated in Figure 1.11. Approximately 31% of 316 ovarian serous
cystadenocarcinoma tumor samples have alterations at the level of mRNA
(2011).
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Figure 1.10. Allelic Imbalance of EDD from (Clancy, Henderson et al. 2003)

“Key:
allelic imbalance,
denotes no data available”

heterozygote,

uninformative homozygote, gap

Figure 1.11. EDD levels are regulated at the mRNA level through upregulation or
www.cbioportal.org/
Ovarian
Serous
downregulation
(Adapted
from
Cystadenocarcinoma (TCGA, Nature) (2011))
Amplification Mutation

mRNA Upregulation

No change
mRNA
Downregulation

Similarly, a gene cluster on chromosome 8q22, containing edd and grhl2,
was identified to suppress death receptor expression (Dompe, Rivers et al.
2011). This research also revealed that EDD is overexpressed in several cancer
cell lines that are resistant to apoptosis mediated by death-receptor activation.
Specifically, EDD and GRHL2 reduced the expression of the death receptors Fas
and DR5. Induction of apoptosis by death receptors such as Fas receptor and
TRAIL receptor are detailed in the “Apoptosis” section, which describes the
mechanism of extrinsic apoptosis (vide infra). Silencing of EDD, leading to
increased expression of Fas and DR5, was shown to sensitize cancer cell lines
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to ligand induced death receptor activation resulting in apoptosis. This research
suggests that overexpression of EDD, and GRHL2, may offer tumors a
mechanism to evade apoptosis.
EDD is implicated in the activation of necroptosis, a programmed form of
necrosis which is caspase-independent. In response to caspase inhibition, RIP1
kinase and EDD were discovered to mediate JNK activation, resulting in the
transcription of TNFα (Christofferson, Li et al. 2012). EDD interacts with RIP1
and potentially stabilizes this kinase. Through EDD’s interaction with RIP1, JNK
is activated through an unidentified mechanism, which promotes TNFα
transcription. Transcription of TNFα is mediated most likely through the
transcription factors AP-1 and SP1. EDD is required for the production of TNFα
due to caspase inhibition, but EDD does not have a role in TNFα-mediated
necroptosis. Regulation of TNFα may also have roles in apoptosis and
inflammation, although this has not been addressed.
High expression of EDD in women with serous ovarian carcinoma, who
showed an initial response to chemotherapy, is associated with a two-fold
increased risk of recurrence and death (O'Brien, Davies et al. 2008). Even
though protein expression of EDD did not correlate with cisplatin resistance,
O’Brien et al. demonstrated in a cisplatin-resistant ovarian cancer cell line
(A2780-cp70) in which siRNA-mediated knockdown of EDD increased sensitivity
to cisplatin. High EDD expression in serous ovarian tumors reduced the median
relapse time by 2.2 months in these patients (from 17.3 to 15.1 months in
patients with low EDD tumor expression). The increased risk of relapse,
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associated with high EDD expression, decreased median overall survival of
these patients to 33.2 months as compared to 42.5 months for patients with low
EDD expression (O'Brien, Davies et al. 2008). These results emphasize the
significance of EDD in ovarian cancer as well as a potential role in mediating
cisplatin resistance.
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Apoptosis
Apoptosis is defined as a normal cellular process of programmed death.
Characteristics of apoptosis include membrane blebbing, DNA fragmentation,
condensation of the chromatin, and cellular shrinkage. Carl Vogt was the first to
describe the principle of apoptosis in 1842, but apoptosis was not characterized
until 1965 (Clarke and Clarke 2012). John Kerr, Alastair Currie, and Andrew
Wyllie defined apoptosis using an electron microscope (Kerr, Wyllie et al. 1972).
Within tissues, apoptotic cells divide themselves into smaller membrane bound
bodies which undergo phagocytosis from neighboring cells or other phagocytic
cells. This maintains tissue homeostasis. Apoptosis is a highly regulated process
and is controlled by a genetically defined program. Research in Caenorhabditis
elegans first identified the critical genes involved in mediating apoptosis (nuc 1,
ced 3, ced 4, ced 9) (Horvitz 1999). These genes were later found to be
homologous to the human anti-apoptotic and apoptotic proteins described later
(vide infra).
The stimulus for apoptosis determines the genetic program that is
activated in the cell to trigger apoptosis or, in some cases, overcome the cell’s
ability to prevent apoptosis. Extrinsic apoptosis is typically triggered through
ligand binding and stimulation of a death receptor. Examples include tumor
necrosis factor, Fas ligand, and tumor necrosis factor related apoptosis inducing
ligand (TRAIL). These receptors have a cytoplasmic domain with a death domain
which is critical to transmit the death signal from external stimuli to intracellular
signaling pathways. Upon ligand binding, the death domain of the receptor can
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recruit and bind to an adaptor protein. The adaptor protein (such as Fas
Associated Death Domain and TRAIL Associated Death Domain) associates with
procaspase 8 to form a death-inducing signaling complex (DISC) (Ashkenazi and
Dixit 1998). This results in caspase 8 cleavage and activation. Caspases have
proteolytic activity and are crucial for the cleavage and activation of the caspase
cascade to execute apoptosis.
Intrinsic apoptosis is stimulated by stress, DNA damage, or withdrawal of
growth factors, cytokines, or hormones. This pathway converges on the
mitochondria where apoptosis is induced once a mitochondrial permeability
transition pore is opened to decrease the mitochondrial membrane potential and
release factors into the cytosol. The opening of this pore is tightly controlled by a
balance of anti-apoptotic and pro-apoptotic Bcl-2 family proteins localized at the
mitochondrial membrane. Anti-apoptotic proteins include Bcl-2, Bcl-XL, Bcl-XS,
and Mcl-1. Pro-apoptotic proteins include Bax, Bak, Bad, Bim, Bid, Puma, Noxa,
and Bik. The anti-apoptotic proteins exert their effect by heterodimerizing with the
pro-apoptotic proteins. If the pro-apoptotic proteins are allowed to oligimerize, the
mitochondrial pore will be formed from this oligomer. Once the mitochondrial
pore

is

opened,

factors

such

as

cytochrome

c,

Smac/DIABLO,

and

endonucleases are released. Cytochrome c interacts with Apaf-1 and
procaspase 9 to form an apoptosome resulting in caspase 9 cleavage and
activation (Hill, Adrain et al. 2004).
The extrinsic apoptotic pathway can also intersect with the intrinsic
pathway through caspase 8 mediated cleavage of the pro-apoptotic protein Bid to
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tBid to allow for the formation of the mitochondrial pore (Li, Zhu et al. 1998). In
the end, both the extrinsic and intrinsic pathways both converge on an execution
pathway mediated through caspase 3, caspase 6, and caspase 7. These
caspases cleave cellular substrates to induce apoptosis such as PARP,
cytokeratins,

endonucleases,

and

cytoskeletal proteins.

This

results

in

accumulation of DNA damage due to PARP cleavage, membrane blebbing, and
cell shrinking due to degradation of cytoskeletal proteins and cytokeratins. Also,
endonucleases degrade the chromosomal DNA. Ultimately, all of the normal
cellular processes fail and apoptotic cells neglect maintenance of the
phospholipid bilayer. This allows for phosphatidylserine to be exposed on the
surface of these cells and their cellular fragments to serve as a signal for
phagocytic uptake (Fadok, de Cathelineau et al. 2001).
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Hypothesis
EDD regulates survival and cisplatin resistance in ovarian cancer cells and
oral squamous cell carcinoma

Specific Aims
This hypothesis will be tested through the following specific aims:
B.3. Specific Aims
1. Identify the importance of EDD in regulating survival in ovarian
cancer
1a: Establish if EDD knockdown with siRNA induces apoptosis in
ovarian cancer cell lines
1b. Examine the changes in apoptotic and anti-apoptotic proteins due
to EDD knockdown resulting in apoptosis
1c. Validate the importance of specific proteins by knockdown and
overexpression to induce apoptosis in ovarian cancer cells
1d. Determine the mechanism by which EDD regulates alterations in
specific apoptotic and/or anti-apoptotic proteins
2. Determine if EDD regulates cisplatin sensitivity in ovarian cancer
2a: Determine if EDD knockdown with siRNA and shRNA promotes
cisplatin sensitivity
2b: Determine if EDD overexpression is sufficient to promote cisplatin
resistance
2c: Establish if EDD is a therapeutic target in epithelial ovarian cancer
through EDD knockdown experiments in vivo
3. Characterize the role of EDD in the regulation of cisplatin
resistance in oral squamous cell carcinoma
3a. Generate inducible shRNA EDD knockdown cell lines
3b. Determine if EDD stable knockdown sensitizes squamous cell
carcinoma cell lines to cisplatin treatment
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Chapter 2
EDD regulates cellular survival in ovarian cancer cells

*Note: This chapter contains a portion of the paper:
Carcinogenesis. 2014 May 1; volume 35, number 5, pages 1100-1109.
EDD enhances cell survival and cisplatin resistance and is a therapeutic
target for epithelial ovarian cancer.
Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer
JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood
AK, Landen CN Jr, Eblen ST.
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Introduction
Initial therapy for ovarian cancer involves surgical debulking combined
with chemotherapy, which consists of platinum and paclitaxel; however,
resistance to chemotherapy often occurs in recurrent tumors. One indicator of
poor prognosis in recurrent ovarian cancer is the E3 ubiquitin ligase EDD (E3
ligase identified by differential display), a 300kDa nuclear phosphoprotein that we
previously identified as a direct substrate of the MAP kinase extracellular signalregulated kinase 2 (Henderson, Russell et al. 2002, Eblen, Kumar et al. 2003,
O'Brien, Davies et al. 2008, Bethard, Zheng et al. 2011). EDD helps regulate the
DNA damage response, mediates Chk2 kinase activation, and has been
implicated in the S phase and G2/M DNA damage checkpoints (Henderson,
Russell et al. 2002, Henderson, Munoz et al. 2006, Munoz, Saunders et al. 2007,
Gudjonsson, Altmeyer et al. 2012). EDD also acts as a transcriptional coactivator for the progesterone and vitamin D receptors, dependent upon its
middle domain and independent of its E3 ligase activity (Henderson, Russell et
al. 2002).
EDD protein is overexpressed or mutated in several solid tumors including
ovarian, breast, hepatocellular, tongue, gastric, and melanoma (Mori, Sato et al.
2002, Clancy, Henderson et al. 2003, Fuja, Lin et al. 2004). EDD protein levels
are low in benign ovarian tissue and borderline tumors, but overexpression is
observed in 47% of ovarian cancer tumors overall, 73% of serous ovarian
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tumors, and was associated with a 2-fold increased risk of recurrence and death
in patients who had a favorable response to initial chemotherapy (Clancy,
Henderson et al. 2003, O'Brien, Davies et al. 2008). In these results, I
demonstrate that EDD directly contributes to cellular survival through
upregulation of the anti-apoptotic protein myeloid cell leukemia sequence 1 (Mcl1) in ovarian cancer cells.
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Materials and Methods
Cell lines and antibodies
ES-2 and TOV21G cells were from Runzhao Li, OVCAR3 cells were from Kristen
Atkins, A2780 cells were from Andrew Godwin, A2780ip2 cells were from
Charles Landen, OVCAR5 cells were from Thomas Hamilton and IOSE cells
were from Nelly Auersperg. COS-1, HeLa, and SKOV-3 cells were from
American Type Culture Collection (ATCC, Manassas, VA). Mcl-1 stable cells
were generated by transduction with pBabe or pBabe-Flag-Mcl-1 (Addgene) and
puromycin-resistant clones (A2780ip2) or populations (ES-2) were selected.
Antibodies [poly(ADP-ribose) polymerase (PARP), Bcl2 family proteins, actin]
were from Cell Signaling (Danvers, MA) and the EDD (M19) antibody was from
Santa Cruz Biotechnology (Santa Cruz, CA). Lipofectamine 2000 (Invitrogen)
was used for transfections, according to the manufacturer’s protocol.
siRNA transfection
Cell lines were transfected with 45 nmol of control or EDD siRNA (Sigma–
Aldrich).
siRNA2:

siRNA1:

SASI_Hs01_00175227

SASI_Hs02_00348492

(5′CCAUUUACCCUGGCUAGUA);

(5′GCGACUCUCCAUGGUUUCU).

Mcl-1

siRNA: SASI_Hs01_00162656 (5′GUAAUAGAACUAUGACUGU). Bcl-xL siRNA:
SASI_Hs01_00165963 (5′CUGAUUGGUGCAACCCUUA). Glycogen synthase
kinase 3 beta (GSK-3β) siRNA1: SASI_ Hs01_00192106 (5′GGACUAUGU
UCCGGAAACA) and GSK-3β siRNA2: SASI_Hs01_00192105 (5′CACUCAA
GAACUGUCAAGU). Twenty nanomoles of Mcl-1, Bcl-xL and GSK-3β siRNA
were used. Control siRNA was Universal Negative Control #1 (Sigma–Aldrich).
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Western blotting
Floating and adherent cells were lysed with M2 lysis buffer containing 0.5%
sodium dodecyl sulfate (Eblen, Catling et al. 2001). Typically, 65 µg of protein
lysate

was

separated

by

sodium

dodecyl

sulfate–polyacrylamide

gel

electrophoresis (7–12% gradient gel) and immunoblotted proteins were
visualized using enhanced chemiluminescence (Pierce). GSK-3β inhibitors used
were LiCl (20mM, Sigma–Aldrich), TDZD-8 (10 µM) and L803-mts (20 µM, EMD
Chemicals, Gibbstown, NJ). Cycloheximide (Sigma–Aldrich) was used at 50
µg/ml. For caspase inhibition, cells were co-treated with siRNA and either 25 µM
pan caspase inhibitor Q-VD-OPH (R&D Systems, Minneapolis, MN) or the
negative control Z-FA-FMK (BD Pharmingen, Franklin Lakes, NJ).
Crystal violet staining
Cells were fixed with 4% paraformaldehyde, stained with 0.05% crystal violet in
2% ethanol for 15 min, washed five times with phosphate-buffered saline and
dried. Stained cells were solubilized with 2% sodium dodecyl sulfate in
phosphate-buffered saline and absorbance was measured at 550 nm.
Quantitative real-time PCR
RNA was extracted using the Qiagen (Valencia, CA) RNeasy Plus Mini Kit and
cDNA was synthesized using the Bio-Rad (Hercules, CA) iScript™ Advanced
cDNA Synthesis Kit for RT-qPCR. Bio-Rad’s SsoAdvanced™ SYBR® Green
Supermix was used for quantitative real-time PCR on an Eppendorf (Hauppage,
NY) Mastercycler Realplex 2. The average fold change of the test sample over
control

sample

was

determined

for
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each

experimental

condition

with

normalization to two housekeeping genes, actin and glyceraldehyde 3-phosphate
dehydrogenase. The Mcl-1 primer was from Integrated DNA Technologies
(Coralville, IA) (forward: 5′-AAAGAGGCTGGGATGGGTTT-3′, reverse: 5′-CAAAA
GCAAGCAGCACATTC-3′). The actin primer used was from Real-Time Primers
(forward:

5′-GGACTTCGAGCAAGAGATGG-3′,

reverse:

5′-AGCACTGTGT

TGGCGTACAG-3′) along with glyceraldehyde 3-phosphate dehydrogenase
(forward:

5′-GAGTCAACGGATTTGGTCGT-3′,

reverse:

5′-TTGATTTTGG

AGGGATCTCG-3′).
Flow cytometry
Floating and adherent cells were fixed in ethanol and stained with propidium
iodide (Molecular Probes, Eugene, OR). DNA content was determined by flow
cytometry and sub-2n cells were counted as apoptotic. The Student’s t-test was
performed on three independent experiments done in duplicate.
Luciferase assays
HeLa cells were transfected with 40 ng TK Renilla luciferase, 400ng of the firefly
luciferase plasmids p(−2389/+10)mcl-luc, p(−1289/+10)mcl-luc, p(−567/+10)mclluc, p(-70/+10)mcl-luc, or empty mcl-luc (Chao, Wang et al. 1998) and 2 µg of
either wild-type or mutant Flag-EDD or empty vector. Luciferase assays were
performed at 48hr using the Dual Luciferase Reporter Assay (Promega) on a
Monolight 2010 Luminometer (Analytical Luminescence, Ann Arbor, MI). Firefly
luciferase activity was normalized to Renilla luciferase. The results are a
combination of four independent experiments done in triplicate. After averaging
over experimental replicates, a two-sample t-test was conducted for each
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luciferase plasmid testing the effect of EDD or EDD mutant versus vector. Cell
lysates were immunoblotted for EDD and actin.
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Results
EDD knockdown induces apoptosis in ovarian cancer cells
Immunoblotting lysates from ovarian cell lines showed high EDD
expression in five of seven ovarian cancer cell lines compared with the
preneoplastic IOSE398 cell line, with the highest expression in ES-2, OVCAR5
and A2780 cells (Figure 2.1A). To determine the effect of EDD knockdown, we
transfected A2780ip2 (Figure 2.2A), ES-2 (Figure 2.2B) and OVCAR5 (Figure
2.2C) cells with control siRNA or one of two EDD siRNAs. EDD siRNAs knocked
down EDD protein expression, with siRNA1 having the strongest effect.
Interestingly, cells transfected with EDD siRNA showed a significant reduction in
cell number in all three cell lines within 48hr, as measured by quantitation of
crystal violet staining, with the exception of siRNA2 in ES-2 cells (Figure 2.2D).
Loss of cell viability after EDD siRNA1 transfection increased from 24 to 72hr
(Figure 2.2E). To determine whether EDD knockdown induced apoptosis, lysates
from floating and adherent siRNA-transfected cells were immunoblotted for
cleavage of PARP, a substrate of caspases and an indicator of apoptosis.
Enhancement of cleaved PARP relative to total PARP (cleaved plus uncleaved)
was observed in all three cell lines after EDD siRNA transfection (Figure 2.1B–
D), with siRNA1 having a greater effect, coinciding with greater EDD knockdown,
especially in ES-2 cells. A2780ip2 cells showed enhanced apoptotic sensitivity to
EDD knockdown at earlier time points (Figure 2.1B). In addition, propidium iodide
staining followed by flow cytometry showed significant apoptosis, measured by
<2n DNA content, after 48hr of EDD knockdown in A2780ip2 (control = 5.8%;
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EDD = 44.6%), ES-2 (control = 5.8%; EDD = 42.6%) and OVCAR5 (control =
5.9%; EDD = 22.6%) cells (Figure 2.1E). The induction of apoptosis showed a
temporal increase in both A2780ip2 (Figure 2.1F) and ES-2 cells (Figure 2.1G).
The relatively rapid induction of apoptosis suggested a short EDD half-life and
strong requirement for cell survival. Cycloheximide experiments demonstrated
the half-life of EDD protein was ~4hr in A2780ip2 cells (Figure 2.1H).
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Figure 2.1

51

Figure 2.1. EDD is overexpressed in ovarian cancer cell lines and EDD
knockdown induces apoptosis. (A) EDD expression was determined by
immunoblotting lysates from ovarian cell lines. (B) A2780ip2, (C) OVCAR5 and
(D) ES-2 cells were transfected with control siRNA or one of two siRNAs to EDD.
After transfection for the indicated time, floating and adherent cells were
harvested and cell lysates were immunoblotted for EDD expression and PARP.
Uncleaved (Un) and cleaved (Clv) PARP are indicated with arrows. (E) Cells
were transfected with control siRNA or EDD siRNA1 for 48hr and floating and
adherent cells were stained with propidium iodide. Flow cytometry was used to
determine the percentage of cells with sub-2n DNA content, an indicator of
apoptosis. The results are from three independent experiments. (F) A2780ip2
cells were transfected with control siRNA or EDD siRNA1 for 12 or 24hr and
lysates from floating and adherent cells were immunoblotted for EDD expression
and PARP cleavage. (G) ES-2 cells were transfected with control siRNA or EDD
siRNA1 for 24 or 48hr and lysates from floating and adherent cells were
immunoblotted for EDD expression and PARP cleavage. (H) A2780ip2 cells were
treated with 50 µg/ml of cycloheximide for the indicated time. Cell lysates were
immunoblotted for EDD and actin. The number under each lane indicates the
relative intensity of the EDD band compared with actin, with the amount in time
zero set at 1.
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Figure 2.2
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Figure 2.2. EDD knockdown reduces cellular survival. (A) A2780ip2, (B) ES-2
and (C) OVCAR5 cells were transfected with control or EDD siRNAs for 24hr and
immunoblotted for EDD expression. (D) EDD knockdown reduces cell viability.
Cells were transfected with control or EDD siRNA for 24hr, fixed, stained with
crystal violet, and photographed at 10X magnification. The cells were solubilized
and crystal violet absorbance measured. The number under each photograph
corresponds to absorbance relative to control siRNA in that cell line and
statistical significance from control transfected cells (p<0.05) is indicated with an
asterisk (*). The results are from three independent experiments. (E) A2780ip2
cells were transfected with control siRNA or EDD siRNA1 for 24, 48, or 72hr and
processed as in (D).
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EDD knockdown causes loss of Mcl-1 through a degradation- independent
mechanism
To

identify

a

potential

mechanism

of

apoptosis

induction,

we

immunoblotted siRNA-transfected cell lysates with antibodies to Bcl2 family
members, which have both prosurvival and proapoptotic functions (Burlacu 2003,
Ola, Nawaz et al. 2011). EDD knockdown resulted in specific downregulation of
the prosurvival protein Mcl-1 in all three cell lines, correlating with increased
PARP cleavage (Figure 2.3A), and Mcl-1 loss was detected using either EDD
siRNA1 or siRNA2 (Figure 2.4A). Pretreatment of the cells with the pan caspase
inhibitor Q-VD inhibited PARP cleavage and the loss of the proapoptotic caspase
3 substrate p53 upregulated modulator of apoptosis (Puma) upon EDD
knockdown, but did not inhibit loss of Mcl-1, suggesting that Mcl-1 loss was not a
consequence of caspase action or apoptosis induction (Figure 2.3B) (Hadji,
Clybouw et al. 2010). To compare the requirements for EDD and Mcl-1 in cell
survival, we transfected cells with siRNA against EDD, Mcl-1, the prosurvival
protein Bcl-xL, or control siRNA. Apoptotic cells were identified by propidium
iodide staining. EDD or Mcl-1 siRNA induced equal and significant induction of
apoptosis in A2780ip2 (control = 7.6%; EDD siRNA1 = 42%; Mcl-1 = 41.4%; BclxL = 16.9%) and ES-2 cells (control = 4%; EDD siRNA1 = 25.8%; Mcl-1 = 22.6%;
Bcl-xL = 6.1%), whereas Bcl-xL knockdown induced less apoptosis that was only
significantly different from control in A2780ip2 cells and much less than that
induced by EDD or Mcl-1 siRNA (Figure 2.3C and D). Immunoblotting
demonstrated knockdown of the targeted proteins and levels of PARP cleavage
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that corresponded to the relative level of apoptosis observed by propidium iodide
staining (Figure 2.3E). These data show that these ovarian cancer cell lines have
the same survival requirement for EDD and Mcl-1.
To determine if EDD regulated survival by promoting Mcl-1 levels, we
generated stable cell lines expressing either Flag-Mcl-1 or empty vector. Stable
ES-2 populations (Figure 2.3F) and A2780ip2 clones with varying levels of FlagMcl-1 (Figure 2.3G) were selected with puromycin. Flag-Mcl-1 migrated slower
than endogenous Mcl-1 on sodium dodecyl sulfate–polyacrylamide gel
electrophoresis. Flag-Mcl-1 overexpression inhibited PARP cleavage upon EDD
knockdown in both ES-2 (Figure 2.3H) and A2780ip2 (Figure 2.3I) stable lines
compared with the vector control lines, with a dose-dependent effect of
exogenous Mcl-1 expression on inhibition of PARP cleavage in the A2780ip2
clones. Interestingly, EDD knockdown induced loss of endogenous Mcl-1, but not
expression of the exogenous Flag-Mcl-1 expressed from a cytomegalovirus
promoter. Collectively, these results show that Mcl-1 overexpression protects
cells from apoptosis upon EDD knockdown.
Mcl-1 protein stability is controlled in part through phosphorylation by
GSK-3β, stimulating Mcl-1 ubiquitination by β-transducin repeat-containing
protein, followed by proteosomal degradation (Ding, He et al. 2007). EDD binds
to GSK-3β and stimulates its nuclear accumulation (Hay-Koren, Caspi et al.
2011). To determine if EDD binding to GSK-3β ‘protects’ Mcl-1 from GSK-3βinduced degradation, which would be lost upon EDD knockdown, we transfected
parental A2780ip2 cells with EDD siRNA1 and treated the cells with the GSK-3β
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inhibitors TZDZ, lithium chloride or L803-mts (Klein and Melton 1996, Phiel and
Klein 2001, Martinez, Alonso et al. 2002, Kaidanovich-Beilin and Eldar-Finkelman
2006, Rao, Hao et al. 2007). GSK-3β inhibitors did not inhibit Mcl-1
downregulation or PARP cleavage upon EDD knockdown (Figure 2.4B).
Furthermore, GSK-3β knockdown for 24hr prior to EDD knockdown with siRNA1
did not prevent the loss of Mcl-1 protein or inhibit PARP cleavage (Figure 2.4C),
suggesting that Mcl-1 downregulation after EDD knockdown is GSK-3β
independent.
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Figure 2.3
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Figure 2.3. EDD downregulation decreases Mcl-1 protein levels, whereas Mcl-1
overexpression inhibits apoptosis upon EDD knockdown. (A) Cells were either
untreated (none) or transfected with control or EDD siRNA1 for 24hr. Lysates
from floating and adherent cells were immunoblotted for EDD, PARP and Bcl2
family members as indicated. (B) A2780ip2 and ES-2 cells were untreated (none)
or transfected with control siRNA or EDD siRNA1 and simultaneously treated
with either Q-VD-OPH pan caspase inhibitor (+) or the negative control Z-FAFMK (−). After 24hr, floating and adherent cells were collected, lysed, run on
sodium dodecyl sulfate–polyacrylamide gel electrophoresis, and immunoblotted
for EDD, PARP, Mcl-1, Bcl-xL, p53 upregulated modulator of apoptosis, and
actin. (C) A2780ip2 and (D) ES-2 cells were either untreated (none) or were
transfected with the control siRNA, EDD siRNA1, or siRNA to Mcl-1 or Bcl-xL for
24hr. Floating and adherent cells were fixed, stained with propidium iodide, and
the percentage of sub-2n cells determined by flow cytometry. P values represent
significance compared with the control siRNA-transfected cells. (E) Cells were
transfected with siRNA as in (D) for 24hr. Lysates from floating and adherent
cells were immunoblotted to confirm knockdown and to determine PARP
cleavage. (F) Stable populations of ES-2 cells and (G) stable clones of A2780ip2
cells expressing either pBabe vector (Vec) or pBabe-Flag-Mcl-1 (Mcl-1) were
generated by retroviral transduction. Cell lysates were immunoblotted as
indicated. Arrows indicate endogenous Mcl-1 and the slower-migrating Flag-Mcl1. (H) Stable ES-2 or (I) A2780ip2 cells were transfected with control or EDD
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siRNA1 for 24hr and cell lysates immunoblotted as indicated. Arrows indicate
endogenous Mcl-1 and Flag-Mcl-1.
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Figure 2.4

Figure 2.4. EDD regulates Mcl-1 levels through a GSK-3β-independent
mechanism. (A) A2780ip2 cells were transfected with control siRNA, EDD
siRNA1, or EDD siRNA2 and cell lysates were immunoblotted for EDD, PARP,
and Mcl-1. (B) Cells were either untreated (None) or transfected with control
(Con) or EDD siRNA1 (si1) and treated with DMSO or the GSK-3β inhibitors
TDZD-8, LiCl, or L803-mts. Floating and adherent cells were harvested at 24hr
and cell lysates immunoblotted as indicated. (C) A2780ip2 cells were either
untreated (None) or transfected with either control siRNA (Con) or either of two
GSK-3β siRNAs. After 24hr, the cells were transfected again with either control
(Con) or EDD siRNA1. After an additional 24hr, cell lysates from both floating
and adherent cells were immunoblotted as indicated.
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EDD enhances Mcl-1 expression at the messenger RNA level
The above results suggest that EDD may regulate Mcl-1 synthesis, not its
degradation. Indeed, quantitative real-time PCR analysis demonstrated that EDD
knockdown inhibited Mcl-1 messenger RNA (mRNA) expression by 1.87-fold in
both A2780ip2 and ES-2 cells at 12 and 24hr, respectively, compared with
transfection with control siRNA, demonstrating that EDD downregulation inhibits
Mcl-1 transcription (Figure 2.5A).
EDD has been shown to act as a transcriptional co-activator for the
progesterone and vitamin D receptors, independent of the C-terminal ubiquitin
ligase domain (Henderson, Russell et al. 2002). Flag-EDD co-transfection in
HeLa cells enhanced transcription from an Mcl-1 promoter-driven luciferase
reporter p(−2389/+10)mcl-luc by 5-fold when normalized to cotransfected TK
Renilla luciferase (Figure 2.5B) (Chao, Wang et al. 1998). Transfection of the
ubiquitin

ligase-deficient

point

mutant,

Flag-EDD-C2768A,

also

induced

luciferase expression 5-fold. Western blotting confirmed equal EDD expression
(Figure 2.5C). Regulation of the Mcl-1 promoter likely occurs at the region 70 to
203 nucleotides preceding the transcriptional start site (Figure 2.5D).These data
suggest that EDD positively regulates Mcl-1 transcription, independent of its
ubiquitin ligase activity.
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Figure 2.5
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Figure 2.5. EDD regulates Mcl-1 levels through transcriptional regulation. (A)
EDD knockdown inhibits Mcl-1 mRNA expression. ES-2 and A2780ip2 cells were
transfected with EDD siRNA1 for 24 or 12hr, respectively, and RNA was
harvested. Quantitative real-time PCR was performed using Mcl-1-specific
primers. The y-axis represents the fold change in Mcl-1 mRNA in EDD siRNA1transfected cells compared with that in control siRNA-transfected cells. The
results are a combination of three independent experiments. (B) EDD activates
the Mcl-1 promoter. HeLa cells were transfected with p(−2389/+10)mcl-luc, an
Mcl-1 promoter-driven firefly luciferase plasmid, TK Renilla luciferase, and either
Flag-EDD, Flag-EDD-C2768A, or empty vector. Cells were harvested at 48hr and
firefly luciferase activity was normalized to Renilla luciferase activity in each
sample. P values indicate significance (P < 0.05) within a group between FlagEDD- and vector-transfected cells. These results are a combination of four
independent experiments. (C) Western blot of Flag-EDD from (B). (D) As in (B),
HeLa cells were transfected with p(−2389/+10)mcl-luc, p(−1289/+10)mcl-luc,
p(−567/+10)mcl-luc, p(-70/+10)mcl-luc, or empty mcl-luc, with p(-2389/+10) being
the longest Mcl-1 promoter in the luciferase assay. HeLa cells were also
transfected with TK Renilla luciferase and Flag-EDD or empty vector. After 48hr,
luciferase activity was assayed and normalized to Renilla luciferase activity. This
experiment is a representative experiment out of three experiments. An “*”
indicates significance between Flag-EDD and vector-transfected cells (P<0.05).
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Discussion
This study illustrates that EDD enhances cell survival through the
prosurvival protein Mcl-1, an important mediator of survival in ovarian cancer
cells (Shigemasa, Katoh et al. 2002, Simonin, Brotin et al. 2009, Brotin, MeryetFiguiere et al. 2010). EDD knockdown inhibited Mcl-1 mRNA and endogenous
protein expression, whereas EDD overexpression increased Mcl-1 transcriptional
expression in luciferase assays using the murine Mcl-1 promoter. Induction of the
Mcl-1 promoter was independent of EDD’s ubiquitin ligase activity, as mutation of
the critical cysteine residue in the E3 ligase domain still allowed for induction of
the Mcl-1 promoter. This is in agreement with a previous study that showed that
EDD acted as a transcriptional co-activator through the middle third of the
protein, independent of the C-terminal ubiquitin ligase domain (Henderson,
Russell et al. 2002).
Several transcription factors have been demonstrated to regulate Mcl-1
expression, some of which have links to EDD. Platelet-derived growth factor
stimulation of prostate cancer cells enhances Mcl-1 expression via a β-catenin
and hypoxia-inducible factor 1 alpha subunit-dependent pathway and EDD
ubiquitinates β-catenin to promote its stabilization, nuclear localization and
activity (Hay-Koren, Caspi et al. 2011, Iqbal, Zhang et al. 2012). E2F
transcription factor 1 represses Mcl-1 expression and knockdown of EDD
induces E2F transcription factor 1 protein levels in HeLa cells (Croxton, Ma et al.
2002, Munoz, Saunders et al. 2007). Transcription factor software analysis
(TFSEARCH) of the human Mcl-1 promoter (accession no. DQ088966) identified
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potential binding sites for other transcription factors, including GATAs 1–3, heat
shock factors 1 and 2, nuclear factor kappa B and activator protein 1. The
progesterone receptor cooperates with GATA-2 in transcriptional activation in
breast cancer cells, suggesting that EDD–progesterone receptor interactions
may regulate Mcl-1 expression through a GATA-2-dependent pathway
(Henderson, Russell et al. 2002, Magklara and Smith 2009). We have not ruled
out translational control of Mcl-1 expression by EDD as an additional mechanism
of regulation.
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Chapter 3
EDD increases cisplatin resistance in ovarian cancer cells

*Note: This chapter contains a portion of the paper:
Carcinogenesis. 2014 May 1; volume 35, number 5, pages 1100-1109.
EDD enhances cell survival and cisplatin resistance and is a therapeutic
target for epithelial ovarian cancer.
Bradley A, Zheng H, Ziebarth A, Sakati W, Branham-O'Connor M, Blumer
JB, Liu Y, Kistner-Griffin E, Rodriguez-Aguayo C, Lopez-Berestein G, Sood
AK, Landen CN Jr, Eblen ST.
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Introduction
Initial therapy for ovarian cancer involves surgical debulking combined
with chemotherapy, which consists of platinum and paclitaxel; however,
resistance to chemotherapy often occurs in recurrent tumors. Identifying
mechanisms of acquired drug resistance is important to developing novel
therapeutics. One indicator of poor prognosis in recurrent ovarian cancer is the
E3 ubiquitin ligase EDD (E3 ligase identified by differential display) (Clancy,
Henderson et al. 2003). E3 ubiquitin ligases modify proteins through the addition
of ubiquitin, most often resulting in protein degradation (Wolf and Hilt 2004,
Rechsteiner and Hill 2005). EDD contains a C-terminal HECT (Homologous to
the E6-AP Carboxyl Terminus) ubiquitin ligase domain and is the human
homolog of the Drosophila tumor suppressor hyperplastic discs (hyd), which
regulates imaginal disk formation (Callaghan, Russell et al. 1998). EDD has a
reported role in the DNA damage response and has been implicated in the S
phase and G2/M DNA damage checkpoints (Henderson, Russell et al. 2002,
Munoz, Saunders et al. 2007, Gudjonsson, Altmeyer et al. 2012). EDD enhances
activation of the DNA damage response kinase Chk2 in response to ionizing
radiation or the radiomimetic phleomycin (Henderson, Munoz et al. 2006).
While low in benign tissue and borderline ovarian

tumors, EDD is

overexpressed in 47% of all types of ovarian cancer and 73% of serous ovarian
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tumors (Clancy, Henderson et al. 2003). The EDD protein is also overexpressed
or mutated in several solid tumors including breast, hepatocellular, tongue,
gastric, and melanoma (Mori, Sato et al. 2002, Clancy, Henderson et al. 2003,
Fuja, Lin et al. 2004). EDD is also associated with a 2-fold increased risk of
recurrence and death in patients that initially responded to chemotherapy
(O'Brien, Davies et al. 2008). The edd gene is on chromosome 8q22.3 and
amplification of this chromosomal region is associated with cisplatin resistance
(Wasenius, Jekunen et al. 1997, Callaghan, Russell et al. 1998). Knockdown of
EDD with small interfering RNA (siRNA) decreased colony formation in A2780cp70 ovarian cancer cells, a derivative selected for cisplatin resistance in vitro,
when co-treated with cisplatin (O'Brien, Davies et al. 2008). Collectively, these
results suggest that EDD may play a role in tumor maintenance and/or cisplatin
resistance.
Altered expression of many genes and proteins is reported in tumor tissue
and in isogenic cell lines that have been selected for cisplatin resistance.
However, many of these studies failed to demonstrate that changes in
expression of a particular protein were sufficient to induce cisplatin resistance,
raising the possibility that the observed overexpression of EDD in ovarian tumors
may not be directly responsible for acquired cisplatin resistance. These results
show that EDD directly contributes to cisplatin resistance through its E3 ubiquitin
ligase activity in ovarian cancer cells and provides evidence for EDD as a
therapeutic target for the treatment of epithelial ovarian cancer.
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Materials and Methods

Cell lines and antibodies
ES-2 cells were from Runzhao Li, A2780ip2 cells were from Charles Landen, and
OVCAR5 cells were from Thomas Hamilton.COS-7 cells were from American
Type Culture Collection (ATCC, Manassas, VA). Stable EDD shRNA cells were
generated by retroviral transduction: control shRNA (5′GCTGCAAGACCA
TACACTTAT), EDD-shRNA1 (5′GCTGTAGATTTCAACTTAGAT), EDD-shRNA2
(5′GCCATTAGAAAGAACCACAAA) and EDD-shRNA3 (5′TGACAGCAGAACA
ACATAATT). Puromycin-resistant clones (ES-2 and A2780ip2) or populations
(OVCAR5) were selected. Cisplatin was from Sigma–Aldrich (St Louis, MO).
Poly(ADP-ribose) polymerase (PARP) antibody was from Cell Signaling and the
EDD (M19) antibody was from Santa Cruz Biotechnology (Santa Cruz, CA).
Lipofectamine 2000 (Invitrogen) was used for transfections, according to the
manufacturer’s protocol.
siRNA transfection
Cell lines were transfected with 45 nmol of control or EDD siRNA (Sigma–
Aldrich).

siRNA1:

SASI_Hs01_00175227

siRNA2:

SASI_Hs02_00348492

(5′CCAUUUACCCUGGCUAGUA);

(5′GCGACUCUCCAUGGUUUCU).

Control

siRNA was Universal Negative Control #1 (Sigma–Aldrich).
Western blotting
Floating and adherent cells were lysed with M2 lysis buffer containing 0.5%
sodium dodecyl sulfate (Eblen, Catling et al. 2001). Typically, 65 µg of protein
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lysate

was

separated

by

sodium

dodecyl

sulfate–polyacrylamide

gel

electrophoresis (7–12% gradient gel) and immunoblotted proteins were
visualized using enhanced chemiluminescence (Pierce).
Crystal violet staining
Cells were fixed with 4% paraformaldehyde, stained with 0.05% crystal violet in
2% ethanol for 15 min, washed five times with phosphate-buffered saline and
dried. Stained cells were solubilized with 2% sodium dodecyl sulfate in
phosphate-buffered saline and absorbance was measured at 550 nm.
Flow cytometry
Floating and adherent cells were fixed in ethanol and stained with propidium
iodide (Molecular Probes, Eugene, OR). DNA content was determined by flow
cytometry and sub-2n cells were counted as apoptotic. The Student’s t-test was
performed on three independent experiments done in duplicate.
MTS assay
Stable ES-2 shRNA cell lines were plated in quadruplicate onto 96-well dishes
and treated with cisplatin or saline for 72 h. MTS (3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) reagent (Promega,
Madison, WI) was added for the last 2hr and absorbance measured. The results
are a combination of three independent experiments.
Apoptosis assay
COS-7 cells on coverslips were transfected with 2 µg of Flag-EDD, Flag-EDDC2768A or green florescent protein (GFP). After 24 h, the cells were treated with
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cisplatin for 24hr and fixed with 4% paraformaldehyde. Apoptotic cells were
labeled using the TACS® 2 Tdt-Blue Label In Situ Apoptosis Detection Kit
(Trevigen, Gaithersburg, MD). Flag-EDD-transfected cells were immunostained
with

M2

anti-Flag

antibody

(Sigma–Aldrich),

followed

by

fluorescein

isothiocyanate-labeled secondary antibody (Jackson ImmunoResearch, West
Grove, PA). At least 500 transfected cells per coverslip were counted and the
percentage of transfected apoptotic cells was determined. Four independent
experiments were performed for the cisplatin dose experiment. For the EDDC2768A experiment, three independent experiments were performed comparing
GFP, EDD, and EDD-C2768A at a single dose of 15 µM cisplatin. The data for
GFP compared with EDD included the data from the 15 µM group in the cisplatin
dose experiment, for an n = 7. Two-sample t-tests were conducted to determine
significance.
Intraperitoneal ovarian cancer model and in vivo delivery of siRNA
Female athymic nude mice (NCr-nu) were purchased from the National Cancer
Institute (Frederick, MD) after Institutional Animal Care and Use Committee
approval of protocols and cared for in accordance with guidelines of the
American Association for Accreditation of Laboratory Animal Care. ES-2 and
A2780ip2 cells were suspended in serum-free Hanks' balanced salt solution at a
concentration of 5 × 106 cells/ml, and 1 × 106 cells were injected intraperitoneally
in 200 µl into 40 mice per experiment. After 1 week, mice (n = 10 per group) were
randomized to treatment with (i) 5 µg control siRNA (sense sequence: 5′UUCUCCGAACGUGUCACGU-3′,

Sigma)
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in

1,2-dioleoyl-sn-glycero-3-

phophatidylcholine (DOPC), (ii) 5 µg anti-human EDD siRNA (Sigma product
SASI_Hs01_00175227), (iii) 5 µg control siRNA plus cisplatin or (iv) 5 µg EDDtargeting siRNA in DOPC plus cisplatin. siRNA constructs were incorporated in
DOPC nanoparticles (DOPC) as described previously (Landen, Kinch et al. 2005,
Landen, Merritt et al. 2006) and the lyophilized product was stored at −4°C for <4
weeks. Prior to treatment, the siRNA/DOPC complex was reconstituted in 0.9%
saline and administered intraperitoneally twice per week in a volume of 100 µl.
Cisplatin was administered intraperitoneally at a dose of 40 µg weekly. Mice were
treated for 4 weeks before killing and tumor collection. Tumors were excised and
total tumor weight recorded. Statistical analysis comparisons of tumor weights
were made using a two-tailed Student’s t-test, if assumptions of data normality
were met. Those represented by alternate distribution were examined using a
non-parametric Mann–Whitney U-test. Differences between groups were
considered statistically significant at P < 0.05. Error bars represent standard
error. Number of mice per group (n = 10) was chosen as directed by a power
analysis to detect a 50% decrease in tumor growth with beta error of 0.2.
Immunohistochemistry was performed using anti-EDD antibody.
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Results
EDD knockdown increases cisplatin sensitivity
O’Brien et al. showed that EDD siRNA reduced colony formation after
cisplatin treatment in the cisplatin-resistant A2780-cp70 cell line (O'Brien, Davies
et al. 2008). However, although 72hr cisplatin treatment induced dose-dependent
cell death in ES-2 and A2780ip2 cells transfected with control siRNA (Figure
3.1A and B), the catastrophic apoptosis induced by EDD siRNA obscured any
cisplatin effect. At 24hr of cotreatment, EDD knockdown in ES-2 cells conferred
cisplatin sensitivity (Figure 3.1C), whereas the strong apoptotic response of EDD
knockdown alone in A2780ip2 cells masked any potential effects on cisplatin
sensitization (Figure 3.1D). Although EDD knockdown induced apoptosis in
A2780-cp20 cisplatin-resistant cells, it did not enhance cell death in response to
cisplatin in these cells (Figure 3.1E).
In order to separate the basic cell survival function of EDD from a potential
role in cisplatin resistance, we generated ES-2 (Figure 3.2A), A2780ip2 (Figure
3.2B) and OVCAR5 (Figure 3.2C) cell lines with constitutive knockdown of EDD
using retroviral transduction of three separate shRNAs. These cells represent the
small portion of the population that can survive initial EDD knockdown, as the
majority of the cells undergo apoptosis. Immunoblotting showed that these pools
of cells survive because they are not dependent upon EDD for Mcl-1 expression
(Figure 3.3). Cellular clones of ES-2 and A2780ip2 cells and a population of
OVCAR5 cells were selected. MTS assays demonstrated that ES-2 clones
expressing EDD shRNA were 4- to 21-fold more sensitive to cisplatin than cells
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expressing control shRNA, with EC50 values of 48.8 µM for the control-1 (clone 1)
shRNA line, 12.0 µM for EDD shRNA1, 7.4 µM for EDD shRNA2, and 2.3 µM for
the EDD shRNA3 cell lines (Figure 3.2D). In addition, A2780ip2 (Figure 3.2E)
and OVCAR5 (Figure 3.2F) EDD shRNA cells were more sensitive to cisplatin
after 24hr of treatment compared with the control shRNA cells, as measured by
increased induction of PARP cleavage. These results demonstrate that stable
loss of EDD sensitizes cells to cisplatin.
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Figure 3.1
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Figure 3.1. Transient EDD knockdown may sensitize cells to cisplatin. (A) ES-2
and (B) A2780ip2 cells were transfected with either control siRNA or EDD
siRNA1 and immediately treated with vehicle, 0.3, 1, or 3 µM cisplatin for 72hr.
Photographs were taken at 10X magnification. (C) ES-2 and (D) A2780ip2 cells
were either untreated (None) or transfected with either control siRNA or EDD
siRNA1. Cells were treated with Vehicle (Veh), 1, or 5 µM cisplatin immediately
after transfection and harvested at 24hr for immunoblotting. (E) Apoptosis is
induced in cisplatin resistant cells upon EDD knockdown. A2780 and the
cisplatin-resistant A2780-cp20 cell line were transfected with control siRNA or
EDD siRNA1 and then treated with increasing amounts of cisplatin. Cells were
harvested at 24hr and immunoblotted as indicated.
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Figure 3.2
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Figure 3.2. Stable EDD knockdown increases cisplatin sensitivity. (A) ES-2, (B)
A2780ip2 and (C) OVCAR5 cells were retrovirally transduced with control or one
of three EDD shRNAs and clones (ES-2 and A2780ip2) or populations
(OVCAR5) were selected. Cell lysates were immunoblotted for EDD expression.
Multiple clones from the same shRNA are designated as A or B. (D) ES-2 control
shRNA or EDD shRNA cells were treated with cisplatin for 72h and cell viability
measured by MTS assay. Percent survival was plotted against the log of the
cisplatin concentration. The results are from three independent experiments
performed in quadruplicate. (E) A2780ip2 and (F) OVCAR5 shRNA cells were
treated with cisplatin for 24hr and cell lysates from floating and adherent cells
were immunoblotted for EDD and PARP cleavage. The numbers underneath the
blot represent the relative intensity of cleaved PARP in each lane compared with
the first lane of each blot.
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Figure 3.3

Figure 3.3. Normal Mcl-1 expression in EDD stable knockdowns. A2780ip2, ES2, and OVCAR5 stable knockdown cell lines were immunoblotted for EDD, Mcl-1,
and actin.
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EDD is sufficient to induce cisplatin resistance
To determine if EDD is sufficient to induce cisplatin resistance, COS-7
cells were transfected with Flag-EDD or GFP for 24hr and then treated with
cisplatin for an additional 24hr. Cells were immunostained for Flag-EDD and
costained with the TACS® 2 Tdt-Blue Label In Situ Apoptosis Detection Kit,
staining apoptotic nuclei black under brightfield microscopy (Figure 3.4A). The
percentage of transfected cells that were apoptotic after cisplatin treatment was
determined by counting. Cells transfected with Flag-EDD had significantly less
apoptosis at the higher cisplatin doses of 15 µM (GFP = 8.9%, EDD = 4.0%, P <
0.03) and 30 µM (GFP = 14.6%, EDD = 6.0%, P < 0.02) compared with the GFPtransfected cells, demonstrating that EDD overexpression was sufficient to
induce cisplatin resistance (Figure 3.5A). To determine if EDD ubiquitin ligase
activity was required, cells were transfected with GFP, Flag-EDD, or Flag-EDDC2768A, a ubiquitin ligase-deficient mutant, and treated with 15 µM cisplatin for
24hr. EDD-C2768A did not induce cisplatin resistance compared with the GFP
control, whereas EDD caused 2.4-fold protection (GFP = 9.4%, EDD = 3.8%,
EDD-C2768A = 11.8%) (Figure 3.5B). Statistical significance was seen between
EDD and GFP, and EDD and EDD-C2768A. These results show that EDDinduced cisplatin resistance is dependent upon its E3 ubiquitin ligase activity.
EDD localizes to the nucleus, where cisplatin induces DNA damage, and
mutation of EDD at Cys2768 did not affect nuclear localization (Figure 3.4B)
(Henderson, Russell et al. 2002, Henderson, Munoz et al. 2006).
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Figure 3.4

Figure 3.4. EDD overexpression in apoptosis assay and EDD localization. (A)
COS-7 cells plated on coverslips were transfected with Flag-EDD (24hr) and then
treated with cisplatin for an additional 24hr. Cells were fixed and stained for the
transfected gene (green) and apoptotic (black) cells and DAPI (blue). (B) EDD
mutation does not affect nuclear localization. COS-7 cells on coverslips were
transfected with either Flag-EDD or Flag-EDD-C2768A. The cells were then fixed
and immunostained with anti-Flag antibody followed by FITC-labeled secondary
antibody and DAPI stained.
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Figure 3.5

Figure 3.5. EDD overexpression is sufficient to induce cisplatin resistance,
dependent upon its ubiquitin ligase activity. (A) COS-7 cells on coverslips were
transfected with Flag-EDD or GFP for 24hr and then treated with cisplatin for an
additional 24hr. Fixed cells were stained for transfected and apoptotic cells and
4′,6-diamidino-2-phenylindole stained, as shown in Figure 3.4. The percentage of
apoptotic transfected cells was determined by cell counting. At least 500 cells
were counted per condition in each of four experiments. (B) Same as in (A), but
cells were transfected with GFP, Flag-EDD or Flag-EDD-C2768A, an ubiquitin
ligase-deficient mutant. Cells were treated with 15 µM cisplatin for 24hr on the
day following transfection and the percentage of apoptotic transfected cells was
determined by cell counting 24hr later.
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EDD knockdown in vivo enhances cisplatin efficacy
Charles Landen, Jr. and Anil Sood have previously demonstrated in vivo
delivery of siRNA to ovarian tumors via DOPC liposomal nanoparticles, resulting
in knockdown of the target protein and a reduction in tumor burden (Landen,
Kinch et al. 2005, Halder, Kamat et al. 2006, Landen, Merritt et al. 2006, Lin,
Immaneni et al. 2008, Merritt, Lin et al. 2008, Mangala, Han et al. 2009,
Chakravarty, Roy et al. 2011, Nick, Stone et al. 2011). To determine if EDD is a
viable target for the treatment of ovarian cancer, we generated intraperitoneal
xenografts of ES-2 and A2780ip2 cells in female athymic nude mice. One week
later, 10 mice per group were treated intraperitoneally twice per week with either
control or EDD siRNA1 in DOPC liposomes, in combination with either cisplatin
or saline treatment once weekly. After 4 weeks, mice were killed and tumor
tissue was harvested. When compared to control siRNA treatment alone,
cisplatin combined with control siRNA/DOPC showed a trend toward significance
in ES-2 xenografts when measuring tumor weight (37.7% reduction, P = 0.167)
but became statistically significant when cisplatin was combined with EDD
siRNA1/DOPC (77.9% reduction, P = 0.004) (Figure 3.6A). In A2780ip2
xenografts, cisplatin plus control siRNA/DOPC treatment was not significantly
different compared with control siRNA/DOPC alone (39.2% reduction, P = 0.349),
but cisplatin plus EDD siRNA1/DOPC was significantly better than control
siRNA/DOPC alone (75.9% reduction, P = 0.042). In those mice treated with
cisplatin, cotreatment with EDD siRNA1/DOPC was significantly better than cotreatment with control siRNA/DOPC in ES-2 (64% reduction, P = 0.035) and
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showed a trend toward significance in A2780ip2 (60.3% reduction, P = 0.168).
Immunohistochemistry of A2780ip2 tumors with EDD antibody showed EDD
expression in tumors treated with control siRNA, with a possible enhancement of
EDD expression in tumors following cisplatin treatment (Figure 3.6B and C). EDD
siRNA1 treatment in vivo decreased EDD expression in tumors (Figure 3.6D and
E). Collectively, these results suggest that therapies targeting EDD expression
might be an attractive treatment for ovarian cancer patients.
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Figure 3.6
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Figure 3.6. DOPC nanoparticle delivery of EDD siRNA in vivo reduces tumor
burden. (A) ES-2 or A2780ip2 cells were injected intraperitoneally into 40 female
athymic nude mice per cell line. Mice were either treated with control siRNA in
DOPC (lane 1), EDD siRNA1 in DOPC (lane 2), control siRNA in DOPC plus
cisplatin (lane 3), or EDD siRNA1 in DOPC plus cisplatin (lane 4). Mice were
treated for 4 weeks before killing and tumor collection. Tumors were excised and
total tumor weight determined. The number above each lane represents the
mean tumor weight in grams. Immunohistochemistry demonstrates EDD
knockdown in vivo. A2780ip2 tumors from mice treated with (B) control siRNA in
DOPC, (C) control siRNA in DOPC plus cisplatin, (D) EDD siRNA1 in DOPC and
(E) EDD siRNA1 in DOPC plus cisplatin were immunostained with EDD antibody
followed by horseradish peroxidase secondary antibody.
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Discussion
These results show that EDD directly regulates cisplatin sensitivity. A
previous study has shown that EDD overexpression correlates with poor survival
for patients with recurrent ovarian cancer and that knockdown of EDD with siRNA
in cisplatin-resistant A2780-cp70 cells decreases colony formation by 40% after
cisplatin treatment (O'Brien, Davies et al. 2008). However, a portion of this effect
may be due to the cell survival functions of EDD described in the previous
chapter. To separate these functions, we generated stable knockdown cells to
select for those cells that could survive initial EDD knockdown. These cells
showed normal levels of Mcl-1, demonstrating that this small portion of the initial
cell population was not dependent upon EDD for Mcl-1 expression. By separating
these functions, we demonstrated that loss of EDD sensitizes cells to cisplatin.
Expression of EDD in ovarian cancer cell lines does not directly correlate with
reported cisplatin sensitivity, as some ovarian cancer cell lines with high EDD
expression have low cisplatin IC50s and some of those with higher resistance
express lower levels of EDD (Figure 2.1 and Table 3.1) (Smith, Ngo et al. 2005,
Matsumura, Huang et al. 2011, Ye, Fu et al. 2011, Saran, Arfuso et al. 2012).
This is likely due to the multiple mechanisms of cisplatin resistance in cells and
tumors (Galluzzi, Senovilla et al. 2012). Indeed, A2780-cp70 cells selected in
vitro for cisplatin resistance after long-term exposure did not have higher levels of
EDD expression than parental A2780 cells (O'Brien, Davies et al. 2008).
Importantly, we show that overexpression of EDD was sufficient to induce
resistance to cisplatin and was dependent upon EDD ubiquitin ligase activity.
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EDD has been suggested to play a role in the DNA damage response,
particularly in response to double strand breaks. EDD and the E3 ubiquitin ligase
TRIP12 regulate levels of RNF168, a regulator of histone ubiquitination after
DNA damage, resulting in controlled spread of histone ubiquitination from the
area of double strand breaks (Gudjonsson, Altmeyer et al. 2012); however, no
reports have linked RNF168 to cisplatin resistance. EDD is important in activation
of the DNA damage response kinase Chk2, as EDD-depleted cells show reduced
activation of Chk2 in response to double strand breaks (Henderson, Munoz et al.
2006). EDD knockdown increased sensitivity of HeLa cells to phleomycin,
regulating both the S phase and the G2/M phase checkpoints in treated cells
(Henderson, Munoz et al. 2006, Munoz, Saunders et al. 2007, Benavides, ChowTsang et al. 2013). In the presence of DNA damage, EDD knockdown cells
underwent radio-resistant DNA synthesis and premature entry into mitosis,
leading to mitotic catastrophe (Munoz, Saunders et al. 2007).
Both Bcl-xL and Mcl-1 have been implicated to protect ovarian cancer
cells from chemotherapy-induced apoptosis, suggesting that EDD upregulation of
Mcl-1 expression (as described in the previous chapter) may also contribute to
cisplatin resistance; however, the requirement for ubiquitin ligase activity for
cisplatin resistance, but not for induction of the Mcl-1 promoter, strongly suggests
that the regulation of Mcl-1 by EDD is distinct from the induction of cisplatin
resistance as illustrated in Figure 3.7 (Simonin, Brotin et al. 2009). Interestingly,
EDD itself appeared to be upregulated in xenografts from mice treated with
cisplatin, which may be clinically important in regards to a study showing EDD
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overexpression in recurrent ovarian tumors from patients who had a favorable
response to initial chemotherapy (O'Brien, Davies et al. 2008).
Small molecule inhibitors of ubiquitin ligases have had little success due to
the lack of a defined catalytic domain and the utilization of protein–protein
interactions in order to ubiquitinate targets. Charles Landen, Jr. and Anil Sood
have previously demonstrated that DOPC nanoparticles can be utilized to
efficiently deliver siRNA to ovarian tumor tissue to inhibit tumor growth and
metastasis and to enhance chemosensitivity (Landen, Kinch et al. 2005, Halder,
Kamat et al. 2006, Landen, Merritt et al. 2006, Lin, Immaneni et al. 2008, Merritt,
Lin et al. 2008, Mangala, Han et al. 2009, Chakravarty, Roy et al. 2011, Nick,
Stone et al. 2011). Our in vivo data demonstrated that EDD is a valid target for
treating epithelial ovarian cancer in combination with chemotherapy. EDD siRNA
showed enhanced efficacy over cisplatin treatment alone in ES-2 xenografts and
a trend toward significance in A2780ip2 xenografts. This effect of EDD siRNA
was likely due to both the positive effects of EDD on cell survival and the
enhancement of cisplatin resistance. Upon knockdown in vivo, loss of EDD likely
enhances both cell death and cisplatin sensitivity. Our findings that EDD
regulates survival Mcl-1 regulation independent of its ubiquitin ligase activity and
cisplatin resistance through its ubiquitin ligase domain suggest that therapies
targeting EDD expression, such as EDD siRNA in nanoparticles, may prove to be
a more beneficial therapeutic approach than a chemical inhibitor of EDD ubiquitin
ligase activity, although the latter alone may have some beneficial role in
enhancing cisplatin sensitivity.
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Figure 3.7

Figure 3.7. Model for EDD regulation of survival and cisplatin resistance. EDD
enhances cell survival by promoting Mcl-1 transcriptional expression through
regulation of an unknown transcription factor (TF). Enhancement of Mcl-1 protein
expression is independent of GSK-3β inhibition of Mcl-1 protein levels. EDD also
increases cisplatin resistance through its E3 ubiquitin ligase function.
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Table 3.1
Ovarian
Cell Line
IOSE

IC50
(µM)
3.17

Cisplatin Reference

A2780

1.74

(Matsumura, Huang et al. 2011)

ES-2

48.8

(Bradley, Zheng et al. 2014)

OV2008

1.72

(Ye, Fu et al. 2011)

OVCAR3

25.7

(Smith, Ngo et al. 2005)

OVCAR5

5.02

(Matsumura, Huang et al. 2011)

SKOV-3

21.7

(Smith, Ngo et al. 2005)

TOV-21G

18.5

(Smith, Ngo et al. 2005)

(Saran, Arfuso et al. 2012)

Table 3.1. Cisplatin sensitivities across ovarian cancer cell lines. The reported
IC50 to cisplatin of the cell lines used in this study and the references they are
from. The number from ES-2 cells was derived from our data (Figure 3.2).
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Chapter 4
EDD regulates cisplatin resistance in oral squamous cell carcinoma
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Introduction
Oral squamous cell carcinoma is diagnosed in more than 40,000
Americans each year, with 20% of these patients ultimately dying from this
disease (Siegel, Naishadham et al. 2013). Oral cancer is of primary concern
worldwide since it affects over 330,000 people each year with 54% of these
patients eventually dying from this type of cancer (Parkin, Bray et al. 2005). Even
though most oral squamous cell carcinomas remain localized, some patients
experience metastasis to the lymph nodes, which is often difficult to treat even
after surgery and radiation. To combat this issue, patients with metastasis are
typically treated with chemotherapeutic drugs such as cisplatin, paclitaxel, and 5fluorouracil. Drug resistance in this type of carcinoma is a reality, but is not highly
studied.
The E3 ubiquitin ligase EDD is genetically amplified in 50% of oral
squamous cell carcinomas of the tongue (Clancy, Henderson et al. 2003). This is
similar to ovarian cancer where edd is upregulated in 47% of ovarian cancers
(73% of serous ovarian cancers) and this cancer is also commonly treated with
cisplatin often leading to drug resistance (Clancy, Henderson et al. 2003). My
previous research in ovarian cancer demonstrated that EDD is sufficient to
promote cisplatin resistance in ovarian cancer, which is dependent on its
ubiquitin ligase activity, as described in Chapter 3 and in my recent publication
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(Bradley, Zheng et al. 2014). Based on this research, this led me to hypothesize
that EDD may also be involved in mediating cisplatin resistance in oral squamous
cell carcinoma since both oral cancer and ovarian cancers are treated with
cisplatin and edd is upregulated in both.
EDD ubiquitinates several proteins to regulate their degradation (TopBP1,
Paip2, Katanin p60, TERT, and RNF168) or stability (βcatenin) (Honda, Tojo et
al. 2002, Yoshida, Yoshida et al. 2006, Maddika and Chen 2009, Gudjonsson,
Altmeyer et al. 2012, Jung, Wang et al. 2013, Okamoto, Bartocci et al. 2013). It is
uncertain at this time which known or unknown ubiquitination targets of EDD are
involved in regulating cisplatin resistance in ovarian cancer. Although a
connection has not been established between EDD and oral squamous cell
carcinoma, overexpression of EDD is correlated with a two-fold increased risk of
disease recurrence in ovarian cancer patients that initially responded to
chemotherapeutic treatment (O'Brien, Davies et al. 2008). My aim is to establish
a connection between EDD and oral squamous cell carcinoma to determine if
EDD regulates cisplatin sensitivity in these cells as well as to determine the
mechanism by which this could be occurring.
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Materials and Methods
Cell lines and antibodies
IOSE cells were from Nelly Auersperg. HeLa and SKOV-3 cells were from
American Type Culture Collection (ATCC, Manassas, VA). UM-SCC-9 and UMSCC-25 cell lines were obtained from Steve Rosenzweig (MUSC). UM-SCC-11A,
UM-SCC-11B, UM-SCC-22B, and UM-SCC-74B cells were from Viswanathan
(Visu) Palanisamy (MUSC). Inducible stable EDD knockdown cell lines were
generated by retroviral transduction with pTRIPZ shRNA (Thermo Scientific,
Waltham, MA): Scrambled control (RHS4743), EDD-shRNA1 (V2THS_202102,
5’TAGAGGAATAGAGTGGGAC), EDD-shRNA2 (V2THS_203176, 5’TTGGAA
TCTACATTCACTG), EDD-shRNA3 (V2THS_75176, 5’TTATTAAAGAATGCAC
ACC). Initial transfection of 3µg shRNA plasmid, 3µg ∆8.91, and 1.5µg pVSV-G
were performed with calcium phosphate transfection according to the
manufacturer’s protocol (Clontech, Mountain View, CA).

Stable populations

were selected with puromycin and shRNA expression was induced with
doxycycline (Sigma-Aldrich, St Louis, MO). Non-inducible stable EDD shRNA
cells

were

generated

by

retroviral

(5′GCTGCAAGACCATACACTTAT),
TAGAT),

EDD-HP2

transduction:

EDD-HP1

control

(5′GCTGTAGATTTCAACT

(5′GCCATTAGAAAGAACCACAAA)

(5′TGACAGCAGAACAACATAATT).

shRNA

Puromycin-resistant

and

EDD-UTR

populations

were

selected. Cisplatin was from Sigma–Aldrich (St Louis, MO). Poly (ADP-ribose)
polymerase (PARP) antibody was from Cell Signaling and the EDD (M19)
antibody was from Santa Cruz Biotechnology (Santa Cruz, CA).
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siRNA transfection
Cell lines were transfected with 45 nmol of control or EDD siRNA (Sigma–
Aldrich).

siRNA1:

SASI_Hs01_00175227

siRNA2:

SASI_Hs02_00348492

(5′CCAUUUACCCUGGCUAGUA);

(5′GCGACUCUCCAUGGUUUCU).

Control

siRNA was Universal Negative Control #1 (Sigma–Aldrich).
Western blotting
Floating and adherent cells were lysed with M2 lysis buffer containing 0.5%
sodium dodecyl sulfate (Eblen, Catling et al. 2001). Typically, 65 µg of protein
lysate

was

separated

by

sodium

dodecyl

sulfate–polyacrylamide

gel

electrophoresis (7–12% gradient gel) and immunoblotted proteins were
visualized using enhanced chemiluminescence (Pierce).
Fluorescence Activated Cell Sorting
Inducible stable EDD knockdown cell lines utilize pTRIPZ shRNA which
expresses red fluorescent protein (RFP). Cells were sorted for the top 25% of
cells expressing the highest levels of RFP. Cells were treated with doxycycline
(0.5µg/mL) daily for one week. Cells (5x106) were trypsinized, centrifuged at
1500rpm for 5 minutes, washed with 1xPBS, and centrifuged again. Cells were
resuspended in 1mL PBS and 1µL of violet LiveDead (Invitrogen) was added,
cells incubated on ice for 30 minutes in the dark. Cells were then centrifuged,
washed with PBS, centrifuged, and resuspended in 500uL Cell Staining Buffer
(PBS + 1%BSA). Finally, cells were filtered through 40uM capped FACS tubes
(BD 352235, BD Biosciences, San Jose, CA) just before being sorted on the
FACS Aria Iiu Cell Sorter in the Flow Cytometry core at MUSC at RFP
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wavelength (553-574nm) and LiveDead violet (405 to 451nm). Cells were sorted
into media +50% FBS +Pen/Strep antibiotic and kept on ice until being
centrifuged, resuspended in media +10% FBS +Pen/Strep +doxycycline
+puromycin, and plated.
Colony Formation Assay
One thousand cells were plated on a 35mm dish. The following day, cells were
treated with cisplatin for 2 hours, washed with PBS, and incubated with fresh
media +10% FBS for 3-7 days. Cells were collected by being washed twice with
PBS and fixed with 4% paraformaldehyde for 20 minutes at room temperature,
washed with PBS, stained with 0.05% crystal violet in 2% ethanol for 15 min,
washed five times with phosphate-buffered saline, and dried. Pictures were taken
of the plates and colonies were counted either manually or with the GelCount
Colony Counter (Oxford Optronix, Abingdon, United Kingdom). Stained cells
were solubilized with 2% sodium dodecyl sulfate in phosphate-buffered saline
and absorbance was measured at 550 nm. For proliferation assays, cells were
collected daily for one week without exposure to cisplatin, stained with crystal
violet, and solubilized in 2% SDS as described above.
MTS assay
Stable ES-2 shRNA cell lines were plated in quadruplicate onto 96-well dishes
and treated with cisplatin or saline for 72hr. MTS (3-(4,5-dimethylthiazol-2-yl)-5(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) reagent (Promega,
Madison, WI) was added for the last 2hr and absorbance measured. The results
are a representation of one experiment.
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Results
Transient knockdown of EDD causes apoptosis in oral squamous cell
carcinoma cell lines
Based on research from Clancy et al., edd is upregulated in 50% of oral
squamous cell carcinomas of the tongue (Clancy, Henderson et al. 2003). To
determine EDD protein expression in oral squamous cell carcinomas, cell lysates
were collected from five different oral squamous cell carcinoma cell lines and
compared to protein expression in SKOV3, an ovarian cancer cell line, and IOSE,
an immortalized ovarian surface epithelium cell line as shown in Figure 4.1A.
While IOSE represents a benign ovarian cell line, a benign oral cell line was not
available for comparison. The UM-SCC-9 cell line is a squamous cell carcinoma
of the anterior tongue from a 25 year old male. UM-SCC-25 cells are cells from a
neck metastasis that initiated in the larynx of a 70 year old male. UM-SCC-11A
cells are from an epiglottis tumor in a male, while UM-SCC-11B cells are from a
cervical lymph node tumor that formed from this primary tumor. UM-SCC-74A
cells were isolated from a tumor at the base of the tongue from a male patient.
UM-SCC-74B cells were isolated from the larynx as the metastatic tumor cells
from UM-74A cells (Brenner, Graham et al. 2010). The EDD protein is highly
expressed in the oral squamous cell carcinoma cell lines analyzed in comparison
to the ovarian cell lines (Figure 4.1A). To establish if EDD is essential in these
cell lines, cells were transfected with control siRNA or one of two different EDD
siRNAs to knockdown EDD expression. EDD siRNA1 has the best ability to
knockdown EDD protein expression and was found in UM11B and UM74B cell
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lines to promote apoptosis, as indicated by the cleavage of the PARP protein
(Figure 4.1B). As seen in ovarian cancer cells, as described in Chapter 2, EDD
knockdown causes a decrease in the protein expression of the anti-apoptotic
protein Mcl-1 as well, which mediates apoptosis in these cells. Apoptosis can
occur in as little as 48 hours after transient EDD knockdown in UM74B cells
(Figure 4.1C).
Repeating this experiment with transient knockdown of EDD with siRNA
using EDD siRNA1 in SCC9, SCC25, UM11A, UM11B, and UM74B cells, we
demonstrated that knockdown of EDD causes apoptosis in SCC25 and UM11B
cell lines as shown in Figure 4.1D. As in Figure 4.1B, EDD transient knockdown
does not cause apoptosis in UM11A cells. In this experiment, UM74B cells did
not undergo efficient knockdown of EDD protein, so a conclusion about
sensitivity to EDD knockdown induced apoptosis cannot be made. Changes in
Mcl-1 protein expression as a result of EDD knockdown were not consistent, in
contrast to those changes seen in Figure 4.1B&C. This indicates that the antiapoptotic protein Mcl-1 may not be required for mediating cellular survival in all
oral squamous cell carcinoma cell lines. SCC9 cells, like UM11A cells, are not
sensitive to EDD knockdown induced apoptosis implying that not all of these oral
squamous cell carcinoma cell lines utilize the same cell signaling pathways to
regulate cell functions such as survival.
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Figure 4.1
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Figure 4.1. SiRNA mediated EDD knockdown causes apoptosis in some oral
squamous cell carcinoma cell lines. (A) Cell lysates from a benign ovarian cell
line (IOSE), ovarian cancer cell line (SKOV3), and five different oral squamous
cell carcinomas were immunoblotted to detect EDD protein expression. (B)
UM11A, UM11B, and UM74B cell lines were transfected with control siRNA or
two different siRNAs targeting EDD for 72 hours. Cell lysates were collected and
blotted for EDD to detect knockdown, PARP to detect apoptosis indicated by the
presence of a lower, cleaved band of PARP, the anti-apoptotic protein Mcl-1, and
Actin for a loading control. (C) UM74B cells were transfected with control siRNA,
EDD siRNA 1, or EDD siRNA 2 for 48 hours. Cell lysates were immunoblotted for
EDD, PARP to detect apoptosis, Mcl-1, and Actin. (D) SCC9, SCC25, UM11A,
UM11B, and UM74B cells were transfected with control or EDD siRNA 1 for 72
hours and immunoblotted for EDD, PARP, Mcl-1, and Actin as described above.
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Transient knockdown of EDD with siRNA increases cisplatin sensitivity in
some oral squamous cell carcinoma cell lines
Based on my research (Bradley, Zheng et al. 2014) and that of O’Brien et
al. (O'Brien, Davies et al. 2008) in ovarian cancer, which demonstrates that EDD
knockdown can increase cisplatin sensitivity, I sought to determine if the same
was true in oral squamous cell carcinoma. Five different oral squamous cell
carcinoma cell lines (SCC9, SCC25, UM11A, UM11B, and UM74B cells) were
transfected with EDD siRNA 1 for 24 hours to knockdown EDD protein
expression (Figure 4.2). Then cells were also treated with a 10 µM dose of
cisplatin for an additional 24 hours. An increase in cell death, and therefore an
increased sensitivity to cisplatin treatment, was determined by the relative
amount of PARP cleavage in comparison to EDD siRNA only treated cells or
control siRNA plus cisplatin treatment. In cell lines that demonstrated both a
good knockdown of EDD and were sensitive to EDD knockdown induced
apoptosis, such as SCC9, SCC25, and UM11B cells, there was also an increase
in cisplatin sensitivity. In SCC9 and SCC25 cells, this is demonstrated by both a
decrease in total uncleaved PARP and a slight increase in cleaved PARP. While
these cell lines are sensitive to both EDD knockdown induced apoptosis and
cisplatin treatment, the combination of the two demonstrates a further increase in
cell death.
In UM11B cells, which are again sensitive to both apoptosis from EDD
knockdown and cisplatin, the combination of the two treatments increases
apoptosis as evidenced by an increase in cleaved PARP. In UM11A cells, as
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shown in Figure 4.1B & C, these cells are not sensitive to EDD siRNA or
cisplatin, but the combination of the two treatments does increase apoptosis
indicating that EDD knockdown may sensitize these cells to cisplatin, whereas
they were not sensitive previously. In this experiment, the only cell line which
definitely does not show increased cisplatin sensitivity after EDD knockdown is
UM74B, but this is due to the fact that there was not a good knockdown of EDD
after transfection with siRNA. More experiments are needed in this cell line to
determine if there is an effect of EDD knockdown to increase cisplatin sensitivity.
Overall, most of the oral squamous cell carcinoma cell lines demonstrated
increased cisplatin sensitivity as a result of EDD knockdown, including one cell
line which was not sensitive to EDD knockdown induced apoptosis.
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Figure 4.2.

Figure 4.2. Transient knockdown of EDD may increase cisplatin sensitivity in
some oral squamous cell carcinoma cell lines. SCC9, SCC25, UM11A, UM11B,
and UM74B cell lines were transfected with control siRNA or EDD siRNA1 for 48
hours and then treated with 10 µM cisplatin for an additional 24 hours. Cell
lysates were immunoblotted for EDD to show protein knockdown, PARP to
indicate apoptosis by the cleavage of PARP, the anti-apoptotic protein Mcl-1, and
actin for a loading control.
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Creation of EDD stable knockdown cell lines
To further test if EDD knockdown increases cisplatin sensitivity, it is
essential to separate the functions of EDD in the regulation of cellular survival
from that in cisplatin resistance. A doxycycline inducible shRNA pTRIPZ plasmid
was used which encodes either: control shRNA, EDD shRNA 1, EDD shRNA 2,
or EDD shRNA 3. This plasmid also encodes an RFP (red fluorescent protein)
expression gene for ease of determining which cells express shRNA. Once a
stable population that expresses the shRNA plasmid is selected for with
puromycin, then doxycycline can be used to turn on the shRNA expression to
knockdown the EDD mRNA and protein expression. This approach also
addresses whether EDD knockdown with shRNA causes apoptosis in these cell
lines (UM22B and UM74B) similar to EDD knockdown with siRNA. After the
addition of doxycycline for at least seven days, RFP expression is visible in a
high percentage of the cells (about 90% in UM74B and about 60% in UM22B
cells). EDD shRNA expression does not appear to cause cell death (results not
shown). Figure 4.3A demonstrates the effectiveness of EDD protein expression
knockdown after the induction of the EDD shRNA in UM22B cells and Figure
4.3B displays this in UM74B cells. Based on these results, it seems that EDD
shRNA 1 and EDD shRNA 3 are the most effective in UM74B and EDD shRNA 3
causes some knockdown in UM22B cells.
In order to obtain a pure population of cells that express the EDD shRNA
plasmid (as evidenced by RFP expression), FACS was used to sort cells for the
top 25% of each stable cell lines that express the highest level of RFP. The
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immunoblot for EDD expression in these stable cell lines is shown in Figure 4.3C,
where UM22B cells do not have adequate knockdown of EDD, but UM74B cells
expressing EDD shRNA 3 have an almost complete loss of EDD protein. These
UM74B cells were tested for cisplatin sensitivity by an MTS assay to evaluate if
stable knockdown of EDD increases cisplatin sensitivity. Figure 4.3D indicates
that UM74B EDD shRNA 3 cells are not more sensitive to cisplatin treatment
over 72 hours than UM74B scrambled shRNA stable cells. Since an MTS assay
measures the relative amount of living cells by detecting mitochondrial activity,
this assay may not be the most appropriate way to measure cisplatin sensitivity.
Cisplatin sensitivity is also measured in these cells by a colony formation assay.
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Figure 4.3.
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Figure 4.3. Inducible stable EDD knockdown in oral squamous cell carcinomas.
(A) UM22B cells were transduced with a lentivirus containing the pTRIPZ plasmid
which includes either a control shRNA or one of three different EDD shRNAs.
After selection of a stable population containing the shRNA with puromycin
selection, shRNA expression in these cells was induced by treatment with
doxycycline for at least seven days. Cells treated with different doses of
doxycycline (0, 0.1, or 1 µg/mL) were lysed and immunoblotted for EDD to detect
knockdown and the anti-apoptotic protein Mcl-1. (B) As in (A), UM74B were
transduced with control or EDD shRNA and the effectiveness of the knockdown
is demonstrated in this immunoblot. (C) UM22B and UM74B cells from (A) and
(B) treated with 1 µg/mL doxycycline for at least one week were sent for FACS
for RFP expression which is encoded on the pTRIPZ plasmid. The top 25% of
cells expressing the highest amounts of RFP were selected and cultured. These
cells were lysed and immunoblotted for EDD to detect knockdown and the antiapoptotic protein Mcl-1. (D) UM74B cells from (C) expressing either the control
shRNA or the EDD shRNA 3 were tested for cisplatin sensitivity by an MTS
assay over 72 hours. This is a graphical representation of one experiment with
samples plated in quadruplicate. Absorbance is normalized to the average
absorbance of untreated cells in each stable cell line.
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EDD stable knockdown reduces colony size in UM74B cells
Based on results from Figure 4.3D, which indicated that an MTS assay
may not be the most appropriate way to measure cisplatin sensitivity in the oral
squamous cell carcinoma cell lines, colony formation assays were used to test
the EDD stable knockdown cells for relative cisplatin sensitivity. Colony formation
assays allow for the analysis of the DNA damage response pathway since these
cells are treated with cisplatin for 2 hours and allowed to repair their DNA over
several days rather than 72 hours of continuous cisplatin treatment as in an MTS
assay. UM74B cells, scrambled shRNA or EDD shRNA 3 overexpressing, were
treated with different concentrations of the chemotherapeutic drug cisplatin (0,
10, 20, 40 µM) for 2 hours and then allowed to recover for 3 days. After 3 days,
cells were collected and the amount of colonies remaining on the plate was
counted (Figure 4.4A). EDD stable knockdown cells (sh3) had slightly fewer
colonies (approximately 27% less at 20 µM) than control scrambled knockdown
cells (Figure 4.4A). This is similar to results published by O’Brien et al in A2780cp70 cells treated with EDD siRNA and 20 µM cisplatin (O'Brien, Davies et al.
2008).
The colonies from the EDD stable knockdown cells appeared to be much
smaller than those in the scrambled control cell lines when treated with cisplatin
(Figure 4.4D). To determine the relative amount of cells on the plate, as
determined by the total amount of crystal violet staining on the colonies, the
absorbance of solubilized crystal violet was measured. EDD stable knockdown
cells had 67% less (at 20 µM) crystal violet staining, and therefore theoretically
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fewer cells, when treated with cisplatin than the scrambled control cells (Figure
4.4B). This difference is also evident over six days of recovery time after cisplatin
treatment as well (Figure 4.4C). Based on these results, it appears that EDD
stable knockdown in UM74B cells slows cellular proliferation when cells are
exposed to cisplatin treatment.
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Figure 4.4.
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Figure 4.4. UM74B stable EDD knockdown cells demonstrate reduced colony
size in cisplatin sensitivity colony formation assays. (A) UM74B scrambled
control shRNA expressing cells and UM74B EDD shRNA3 expressing cells were
plated sparsely, treated for 2 hours with different concentrations of cisplatin, and
colonies were allowed to grow for 3 days before being collected and stained with
crystal violet. The number of colonies was counted and the results from one
experiment are depicted in this graph. The number of colonies in untreated cells
is set to 1 and other conditions are normalized to this number of colonies in the
control. (B) As in (A), after colonies were counted, the crystal violet staining the
colonies was solubilized with 2% SDS and the absorbance was measured at 550
nm. Solubilized crystal violet allows for relative quantitation of total crystal violet
staining taking into account both colony number and colony size. This graph is a
representation of one experiment and absorbance is normalized to the untreated
control cells in each cell line. (C) As in (B), colonies from each stable cell line
were allowed to grow for 3 or 6 days after 2 hours of cisplatin treatment.
Absorbance of solubilized crystal violet staining is normalized to untreated cells.
This graph is a representation of a single experiment. (D) Scrambled shRNA
expressing cells and EDD shRNA3 expressing cells were collected 3 days after 2
hours of 20 µM cisplatin treatment as in (A). These pictures are used to
demonstrate the relative number of colonies and size of colonies on each plate
that were used in (A) and (B).
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EDD stable knockdown does not affect proliferation across oral squamous
cell carcinoma cell lines
To resolve whether EDD stable knockdown has an effect on cellular
proliferation rather than on cisplatin sensitivity, I performed colony formation
assays over time in untreated cells. In order to have another cell line to compare
the UM74B EDD stable knockdown cell line, UM22B cells were transduced with
an EDD shRNA retroviral vector. The UM22B EDD stable knockdown cell line
expressing the UTR (untranslated region) targeted shRNA showed the greatest
knockdown of EDD protein expression as compared to the scrambled control
(Figure 4.5A). A proliferation assay was used to measure colony growth over 7
days daily in UM22B and UM74B scrambled control shRNA and EDD shRNA
expressing cells. There was not a significant difference in cellular proliferation in
the UM22B scrambled and EDD knockdown cell lines over time, but UM74B EDD
stable knockdown cells did grow 31% slower than their scrambled control
counterpart at day 7 (Figure 4.5B).
In order to verify that the effect seen in the UM74B cells is due to EDD
knockdown and not a coincidence of the stable cell line population simply having
a slower rate of proliferation, I performed a proliferation assay with the UM74B
cells scrambled and EDD knockdown with and without doxycycline. Without
doxycycline to activate expression of the shRNA in the cells, the shRNA will not
be expressed and the cells will return to a basal expression of EDD protein.
Figure 4.5C illustrates that the UM74B cells without doxycycline do not grow
significantly slower than the populations treated with doxycycline and therefore
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expressing shRNA (either scrambled or EDD shRNA 3). Comparison of UM74B
scrambled cells with doxycycline to EDD shRNA 3 cells with doxycycline in this
experiment shown in Figure 4.5C indicates that EDD stable knockdown cells do
not have a reduced rate of proliferation in this experiment even though the EDD
knockdown is still present (results not shown). Due to this inconsistency, more
experiments are needed to finally determine if EDD stable knockdown does
indeed reduce proliferation in the UM74B cells. There is not an effect on the
proliferation in the UM22B cells demonstrating that an effect of EDD knockdown
may only be relevant to certain cell lines.
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Figure 4.5
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Figure 4.5. UM74B EDD stable knockdown cells show a reduction in
proliferation. (A) Non-inducible shRNAs, either control or shRNA targeting EDD
(HP2, HP2, and UTR), were transduced into UM22B and UM74B cells, then
populations were selected with puromycin. Cell lysates were collected from these
populations and immunoblotted for EDD to detect protein knockdown. These
same shRNAs were also used in ovarian cancer cells as described in Chapter 3.
(B) UM22B scrambled control shRNA and UM22B EDD shRNA UTR cells from
(A) and UM74B scrambled control shRNA and UM74B EDD shRNA 3 from
(Figure 4.3C) were used in a colony formation assay. Cells were plated sparsely
in doxycycline and colonies after a certain number of days from 1-7 were
collected and stained with crystal violet. Crystal violet staining from each
experimental plate of cells was solubilized with 2% SDS and absorbance was
measured at 550nm. Absorbance of each experimental condition was normalized
to cells from day 1. (C) UM74B scrambled and EDD shRNA 3 expressing cells
either treated with doxycycline for 7 days prior to the experiment and during the
experiment were compared to the same cells that were not treated with
doxycycline. Cells were collected over time as in (B) and absorbance of
solubilized crystal violet in each experimental plate was normalized to cells at
day 1 from each treatment condition.
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EDD stable knockdown sensitizes UM22B cells to cisplatin
Similar to the colony formation assay performed in Figure 4.4, UM22B
stable populations from Figure 4.5A (scrambled shRNA and EDD UTR targeting
shRNA expressing) were treated with cisplatin for 2 hours and colonies were
allowed to recover for three days. Cells were treated with different concentrations
of cisplatin (0, 10, 15, 20, 30, or 40 µM). Results in Figure 4.6A show that at
certain concentrations of cisplatin, UM22B EDD stable knockdown cells are more
sensitive to cisplatin than their scrambled control shRNA counterparts. At a 20
µM dose of cisplatin, EDD knockdown cells are 37% more sensitive to cisplatin
than the scrambled control cell line. This is consistent with results from O’Brien et
al. which demonstrated a similar effect in A2780 cisplatin resistant cells treated
with either scrambled siRNA or EDD siRNA and treated with a 20 µM dose of
cisplatin (approximately 40% increase in sensitivity) (O'Brien, Davies et al. 2008).
Similar to results in Figure 4.5B, Figure 4.6B illustrates that the colony size in
scrambled and EDD shRNA expressing stable cell lines is relatively the same,
indicating that EDD knockdown is not affecting the rate of proliferation in these
cells. A visual representation of the colonies counted in Figure 4.6A is displayed
in Figure 4.6C (UM22B scrambled shRNA expressing cells) and Figure 4.6D
(UM22B EDD UTR targeting shRNA expressing cells). Although there is a
qualitative difference in the number of colonies present in cells treated with 15
µM, 20 µM, and 30 µM doses of cisplatin indicating that EDD stable knockdown
increases cisplatin sensitivity in UM22B cells treated with these certain doses of
cisplatin, otherwise the effect is not significant. These results demonstrate a
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trend towards EDD knockdown fostering cisplatin sensitivity, but more
experiments are required in order to draw a statistically significant conclusion.
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Figure 4.6
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Figure 4.6. UM22B stable EDD knockdown cell lines demonstrate increased
cisplatin sensitivity. (A) UM22B scrambled shRNA and EDD UTR shRNA cell
lines from Figure 4.5A were tested in a colony formation assay to detect changes
in cisplatin sensitivity. Cells were plated sparsely and treated with increasing
concentrations of cisplatin (0, 10, 15, 20, 30, or 40 µM) for 2 hours and then
colonies were allowed to grow for 3 days. Colonies were counted and normalized
to the amount of colonies on the untreated plates. (B) Colonies from (A) were
analyzed for average colony size to determine any differences in the rate of
proliferation in the two different stable cell lines. Pictures of the colonies analyzed
in (A) and (B) are depicted in (C) UM22B scrambled control shRNA
overexpressers and (D) UM22B EDD UTR shRNA overexpressers.
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Discussion
There are certain parallels between ovarian cancer and oral squamous
cell carcinoma cell lines in regards to EDD. As in ovarian cancer, EDD
knockdown in some oral squamous cell carcinoma cell lines promotes apoptosis,
although unlike ovarian cancer, this does not appear to be through regulation of
Mcl-1. EDD knockdown, either transiently or stably, also increases cisplatin
sensitivity in some oral squamous cell carcinoma cell lines. The edd gene is
overamplified in 50% of oral squamous cell carcinoma of the tongue and in 47%
of all types of ovarian cancer (Clancy, Henderson et al. 2003). A commonality
between these two completely different types of cancer that led me to believe
that EDD may be involved in their cellular signaling process is that in addition to
the amplification of edd, both are commonly treated with the DNA-damaging
chemotherapeutic cisplatin and both cancers often display resistance to this
drug. As I have previously shown in ovarian cancer, EDD mediates cellular
survival through the transcriptional regulation of the anti-apoptotic protein Mcl-1
and promotes cisplatin resistance through EDD’s ubiquitin ligase function
(Bradley, Zheng et al. 2014). Before beginning this project exploring the
relationship between EDD and oral squamous cell carcinoma, there was no
connection between this ubiquitin ligase and this cancer other than its gene
amplification.
Presently, the data provided in this chapter demonstrate that the EDD
protein is highly expressed in oral squamous cell carcinoma cell lines and loss of
EDD, in addition to promoting apoptosis in some of these cell lines, can also
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cause cisplatin sensitivity. EDD knockdown induced apoptosis did not appear to
be dependent on regulation of the anti-apoptotic protein Mcl-1. Mcl-1 protein
expression levels were not consistently decreased in response to EDD
knockdown as was seen in ovarian cancer cell lines. This indicates that some of
these cell lines may not be dependent on Mcl-1 or EDD for cellular survival. As
expected, oral squamous cell carcinoma cell lines use different cellular signaling
pathways to regulate survival than ovarian cancer and this can also vary between
cell lines. Bcl-2 may play a more important role in regulating survival in these cell
lines since it has been linked to tumor progression in oral squamous cell
carcinoma (Chen, Kayano et al. 2000).
Cell

lines

(SCC9,

SCC25,

UM11B)

which

experienced

effective

knockdown of EDD in response to siRNA transfection were also more sensitive
to cisplatin. More significantly, one cell line (UM11A), which was consistently not
susceptible to EDD knockdown induced apoptosis or cisplatin treatment, was
sensitive to the combination of the two. This indicates that transient knockdown
of EDD may not be regulating survival in this particular cell line, but it can control
cisplatin sensitivity. In order to separate EDD’s role in maintaining cellular
survival and cisplatin resistance, EDD stable knockdown cell lines were created.
In these cell lines, created with an inducible EDD shRNA, induction of EDD
knockdown did not cause apoptosis as with siRNA mediated knockdown, further
complicating our understanding of signaling pathways in these cells and EDD’s
potential role to promote survival. These stable cell lines may have adopted
alternative signaling pathways to allow for survival without the presence of EDD.
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As seen previously, different cell lines can have vastly different responses
in regards to EDD’s regulation of cisplatin resistance. In UM74B cells, there was
no clear evidence of EDD stable knockdown cells experiencing increased
apoptosis when treated with cisplatin. In this cell line, it appears that loss of EDD
may reduce proliferation when cells are treated with cisplatin. UM74B EDD stable
knockdown cells also demonstrated inconsistent results in proliferation assays
without cisplatin treatment, indicating that these cells may exhibit defects in
proliferation due to EDD knockdown. This is explicable because EDD has been
previously shown in multiple publications to regulate the cell cycle and response
to DNA damage (Henderson, Russell et al. 2002, Gupta, Chakrobarty et al. 2006,
Henderson, Munoz et al. 2006, Munoz, Saunders et al. 2007, Ling and Lin 2011,
Smits 2012). Additional experiments need to be completed in UM74B EDD stable
knockdown cells to examine their ability to respond to other DNA damaging
agents and the mechanism behind this response. Alternatively in UM22B cells
with a stable knockdown of EDD, there was no effect on the proliferation of these
cells when treated with cisplatin. Results from colony formation assays in UM22B
cells indicated that EDD loss in these cells increases cisplatin sensitivity at
certain concentrations of cisplatin (20 µM and 30 µM), which is comparable to
results shown in O’Brien’s research (O'Brien, Davies et al. 2008). The results
described above are summarized in Table 4.1.
Based on these results, it is difficult to draw a direct connection between
EDD and cellular survival or cisplatin resistance, but further experimentation with
other oral squamous cell carcinoma cell lines may lead to more conclusions. The
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cell lines used in these experiments generated considerably different results, so
further exploration of other cell lines may prove to be more beneficial than trying
to focus on a few distinct cell lines. Alternatively, these cell lines (UM74B and
UM22B) could be used for more mechanistic studies to determine the cellular
signaling pathways utilized by each cell line to control responses to DNA
damage, survival, and proliferation. This would allow the delineation of DNA
damage response pathways and cell cycle control pathways in UM74B cells
which demonstrate an alternative rate of proliferation. Ubiquitin ligase function of
EDD could be further explored in UM22B cells, as these cells exhibit increased
cisplatin sensitivity due to the loss of EDD, but only at certain concentrations of
cisplatin. This suggests that a balance may be occurring in these cells between
initial response to DNA damage and a pathway regulated by EDD’s ubiquitination
of another protein at moderate levels of DNA damage when repair is not
effective.
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Table 4.1.
Cell Line

UM11A
UM11B
UM74B

Effective
siRNA
Knockdown
Yes
Yes
Yes

Scc9
Scc25
UM22B

Yes
Yes
Not tested

EDD siRNA
Apoptosis

No
Yes
Yes
Yes
Yes
Not tested

Increased
Cisplatin
Sensitivity
Yes
Yes
Inefficient
knockdown
Yes
Yes
Not tested

Effective
shRNA
Knockdown
Not tested
Not tested
Yes
Not tested
Not tested
Yes

EDD shRNA
Apoptosis

Not tested
Not tested
No
Not tested
Not tested
No

Increased
Cisplatin
Sensitivity
Not tested
Not tested
Reduced
proliferation
Not tested
Not tested
Increased:
14% at 15 µM
37% at 20 µM
33% at 30 µM

Table 4.1. Effects of transient and stable EDD knockdown on apoptosis and
cisplatin sensitivity. Summary of results depicted in Figures 4.1- 4.6 regarding
EDD transient knockdown with siRNA and stable knockdown with shRNA.
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Chapter 5
Conclusion

127

Conclusion
The purpose of this dissertation is to examine the role of the E3 ubiquitin
ligase EDD in modulating cellular survival and cisplatin resistance in both ovarian
cancer and oral squamous cell carcinoma. My experimental approach is as
follows: 1) establish if EDD knockdown with siRNA induces apoptosis; 2)
examine alterations in pro-apoptotic proteins and anti-apoptotic proteins in
response to EDD knockdown induced apoptosis; 3) determine the mechanism by
which EDD alters expression of apoptosis regulatory proteins; 4) determine if
EDD knockdown transiently or stably promotes cisplatin sensitivity in vitro and in
vivo; 5) establish if EDD overexpression is sufficient to promote cisplatin
resistance; 6) resolve if EDD knockdown transiently or stably induces apoptosis
and increases cisplatin sensitivity in oral squamous cell carcinoma.
EDD

knockdown

induces

apoptosis

through

transcriptional

regulation of Mcl-1
Since EDD is overexpressed in ovarian cancer and oral squamous cell
carcinoma, siRNA was used to knockdown EDD in order to determine what
cellular processes required EDD. When EDD is knocked down, cells undergo
apoptosis, which is accompanied by a consistent loss in the anti-apoptotic protein
Mcl-1 in ovarian cancer cell lines. EDD knockdown with siRNA in SCC25,
UM11B, and UM74B oral squamous cell carcinoma cell lines causes apoptosis,
without a consistent change in Mcl-1. This indicates the variety of cellular
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signaling pathways employed by these cell lines as compared to other oral
squamous cell carcinoma cell lines tested and the signaling pathways in ovarian
cancer cell lines.
In ovarian cancer, even when apoptosis is inhibited before EDD
knockdown can cause cleavage of caspases, Mcl-1 protein expression is still
decreased. These cells apparently have an equal requirement for EDD and Mcl-1
for cellular survival as a loss of either results in 23% apoptosis in ES-2 cells and
41% in A2780-ip2 cells. Overexpression of Mcl-1 is sufficient to protect cells from
EDD knockdown induced apoptosis, even though EDD knockdown still results in
a loss of endogenous Mcl-1. Due to the alternative regulation of endogenous
versus exogenous Mcl-1, this led to the deduction that EDD is regulating Mcl-1 at
its promoter, since the exogenous Mcl-1 is driven by a CMV promoter instead of
the endogenous promoter. This assumption was supported by real time PCR in
which EDD knockdown causes a 1.87 fold decrease in Mcl-1 mRNA.
Furthermore, both wild-type EDD and an EDD mutant which lacks ubiquitin ligase
activity were both found to activate transcription from either a direct or indirect
action on the mcl-1 promoter as found in Mcl-1 promoter driven luciferase
assays. These results illustrate that EDD enhances cellular survival in ovarian
cancer cell lines through transcriptional regulation of mcl-1 at its promoter.
Furthermore, this is independent of EDD’s ubiquitin ligase activity.
EDD knockdown sensitizes cells to cisplatin
In addition to being overexpressed in ovarian and oral squamous cell
carcinoma of the tongue, EDD is also associated with a 2-fold increased risk of
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disease

recurrence

and

death

in

patients

that

initially

responded

to

chemotherapy treatment (Clancy, Henderson et al. 2003, O'Brien, Davies et al.
2008). In addition, the amplification of the chromosomal region surrounding EDD
is associated with cisplatin resistance (Wasenius, Jekunen et al. 1997,
Callaghan, Russell et al. 1998). To determine the significance of EDD in
regulating cisplatin resistance in ovarian cancer and oral squamous cell
carcinoma of the tongue, EDD was knocked down transiently with siRNA or
stably with shRNA. In the ovarian cancer cell line ES-2, knockdown of EDD with
siRNA causes apoptosis alone, but when combined with a low dose of cisplatin
treatment, this considerably enhances apoptosis in this cell line. In another
ovarian cancer cell A2780-ip2, knockdown of EDD with siRNA caused such a
substantial amount of apoptosis that it masked any additional effect from cisplatin
treatment. To separate EDD’s functions regarding EDD knockdown induced
apoptosis and increased cisplatin sensitivity, EDD stable knockdown cell lines
were created with EDD shRNA. These cell lines confirmed results that EDD
knockdown increases cisplatin sensitivity across three ovarian cancer cell lines.
EDD stable knockdown cell lines did not show a decrease in the anti-apoptotic
protein Mcl-1 indicating that these two functions of EDD are separate.
Transient knockdown of EDD with siRNA increases cisplatin sensitivity in
some oral squamous cell carcinoma cell lines, such as SCC9, SCC25, UM11B,
and UM11A. Unexpectedly, UM11A cells, which are typically not sensitive to
EDD knockdown induced apoptosis, experienced apoptosis when treated with
both EDD siRNA and cisplatin. This again supports the display of variety across
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the oral squamous cell carcinoma cell lines as well as confirms a role for EDD in
regulating cisplatin sensitivity. This diversity also creates variability in the results
observed in UM74B and UM22B cells with a stable knockdown of EDD using
shRNA expression. UM74B cells appear to exhibit a slower rate of proliferation
when EDD is lost in EDD shRNA stable expressing cells as compared to control
shRNA expressing cells when these cells are treated with cisplatin. Inversely,
UM22B cells with stable knockdown of EDD do not exhibit any alterations in
proliferation with or without cisplatin treatment. These UM22B stable EDD
knockdown cell lines do demonstrate a trend of increased cisplatin sensitivity due
to EDD stable knockdown at certain cisplatin concentrations (20 µM and 30 µM).
Thus, while more experiments are needed in the oral squamous cell carcinoma
cell lines to examine various cell lines, analysis in both ovarian cancer and oral
squamous cell carcinoma demonstrates that knockdown of EDD, transiently and
stably, increases cisplatin sensitivity.
EDD overexpression is sufficient to promote cisplatin resistance,
dependent on its ubiquitin ligase activity
In order to determine the significance of EDD overexpression in
relationship to cisplatin resistance, COS-7 cells were transfected with GFP
(control), wild-type EDD, or C2768A EDD mutant (ubiquitin ligase defective).
After treatment with cisplatin, the percentage of those cells undergoing apoptosis
was measured using a kit that enabled detection by microscopy. Cells that were
transfected with wild-type EDD had significantly fewer cells undergoing apoptosis
due to cisplatin treatment, indicating increased cisplatin resistance in these cells.
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Cells transfected with the ubiquitin ligase defective mutant of EDD (C2768A) did
not increase cisplatin resistance in these cells when compared to the GFP
control transfected cells. As this mutant differs at only one amino acid (cysteine
2768 to alanine), which prevents ubiquitin transfer to a substrate of EDD, this
implies that the ubiquitin ligase function of EDD is required to mediate cisplatin
resistance in these cells. While these experiments were performed in a noncancerous cell line, this indicates that EDD is sufficient when overexpressed to
promote cisplatin resistance, which may be translatable to cancerous cells since
EDD knockdown increases cisplatin sensitivity in these cells lines. Stable cell
lines overexpressing EDD or better transfection efficiency is necessary before
similar experiments could be performed in cancerous cell lines.
EDD is a potential therapeutic target in ovarian cancer
E3 ubiquitin ligases have a catalytic domain, but do not possess a defined
catalytic pocket that would allow small molecule inhibitors to bind. For this
reason, DOPC liposome nanoparticles which encapsulate siRNA targeting EDD
were utilized by our collaborators to deliver EDD siRNA in vivo to athymic nude
mice xenograft models of ovarian cancer. Mice were injected with ovarian cancer
cell lines (ES-2 or A2780-ip2) intraperitoneally and tumors were allowed to
develop for one week. Then mice were treated with control or EDD siRNA in
nanoparticles with or without cisplatin treatment. After four weeks of treatment,
tumors were harvested to reveal that EDD siRNA (without cisplatin) caused a
decrease in tumor burden and when EDD siRNA was combined with cisplatin
treatment this caused a significant reduction in total tumor burden (ES-2 –
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77.9%; A2780-ip2-75.9% reduction compared to control siRNA only treated).
This provides further support for the knockdown of EDD promoting apoptosis and
enhancing cisplatin sensitivity by demonstrating this effect in vivo as a potential
therapeutic strategy. The DOPC liposome nanoparticles encapsulating EDD
siRNA to knockdown EDD is a more attractive therapeutic strategy because loss
of EDD would decrease cellular survival while also increasing cisplatin sensitivity.
If a small molecule inhibitor was used, it would likely only affect one of these two
pathways (either survival or cisplatin sensitivity) since these two pathways are
functionally distinct based on the function of EDD as either a transcriptional coactivator or an E3 ubiquitin ligase.
Conclusion
In conclusion, this dissertation demonstrates that EDD regulates cellular
survival and cisplatin resistance in both ovarian cancer and oral squamous cell
carcinoma. In ovarian cancer, EDD regulates the transcription of the antiapoptotic protein Mcl-1 at both proximal and distal regions of its promoter. This
occurs most likely by EDD acting as a transcriptional co-activator either directly
or indirectly. As a result of EDD’s regulation of Mcl-1, knockdown of EDD
transiently with siRNA promotes apoptosis. Knockdown of EDD, transiently or
stably, increases cisplatin sensitivity in ovarian cancer. Correspondingly, EDD
overexpression is sufficient to increase cisplatin resistance which is dependent
on its ubiquitin ligase function. These results are also confirmed by in vivo mouse
xenograft studies which exhibit EDD knockdown with DOPC liposome
nanoparticles encapsulating siRNA can sensitize ovarian tumors to cisplatin.
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In oral squamous cell carcinoma cells lines, diversity among the cell lines
generates different results depending on the cell line used. Transient knockdown
of EDD causes apoptosis in most oral squamous cell carcinoma cell lines, but
this effect does not appear to be dependent on regulation of Mcl-1. Stable
knockdown of EDD causes a reduced rate of proliferation when UM74B cells are
treated with cisplatin and knockdown of EDD increases cisplatin sensitivity in
UM22B cells treated with certain concentrations of cisplatin.
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Context in the Field
While initial therapies for both ovarian and oral squamous cell carcinomas
are surgical debulking, chemotherapy often follows especially in highly
aggressive cases. Resistance to chemotherapy, such as the DNA damaging
agent cisplatin, is very common. The research in this dissertation concludes that
the E3 ubiquitin ligase EDD is involved with mediating cisplatin resistance in
these cancers. This is of significant importance because the edd gene is
overamplified in both of these types of cancers, including breast, hepatocellular
carcinoma, and metastatic melanoma (Clancy, Henderson et al. 2003, Fuja, Lin
et al. 2004). Previously my mentor Scott Eblen also identified EDD as a direct
substrate of ERK2, implicating EDD as a valuable protein involved in mediating
cell signaling process (Henderson, Russell et al. 2002, Eblen, Kumar et al. 2003,
Bethard, Zheng et al. 2011). There are numerous publications describing EDD’s
roles in DNA damage response, cell cycle control, and transcriptional coactivator. This dissertation research expands upon this knowledge and integrates
it to further demonstrate EDD as a regulator of Mcl-1 transcription to promote
cellular survival and illustrate EDD as an E3 ubiquitin ligase that is sufficient to
increase cisplatin resistance. While more mechanistic studies are needed to
delineate the effectors EDD is interacting with or ubiquitinating to elicit these
effects, this research is critical to establishing EDD as a regulator of cell survival
and drug resistance in two different cancers in which EDD is overexpressed.
EDD was first identified as an ortholog in Drosophila melanogaster which
identified EDD as a critical regulator of proliferation and differentiation (Mansfield,
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Hersperger et al. 1994). This role is supported by my findings that EDD regulates
cellular survival and may control cellular proliferation in certain oral squamous
cell carcinoma cell lines. Similarly, EDD’s role as a transcriptional co-activator for
myocardin, the vitamin D receptor, and the progesterone receptor to control
progestin-induced genes independent of ubiquitin ligase function (Henderson,
Russell et al. 2002, Hu, Wang et al. 2010) is supported by this research. In
addition, EDD regulated the transcription of ACVRL1 to modulate angiogenesis,
and this was also shown to be independent of ubiquitin ligase activity (Chen,
Yang et al. 2013). My documentation of EDD as a transcriptional regulator at the
Mcl-1 promoter further confirms EDD’s role as a transcriptional co-activator,
independent of its ubiquitin ligase activity. Further research is needed to
determine which transcription factors EDD is controlling, either directly or
indirectly, to affect transcription.
In patients that initially responded to chemotherapy, EDD is associated
with a 2-fold increased risk of disease recurrence and death (O'Brien, Davies et
al. 2008). On a genetic level, the amplification of the chromosomal region
surrounding EDD is also linked to increased cisplatin resistance (Wasenius,
Jekunen et al. 1997, Callaghan, Russell et al. 1998). Numerous studies have
been published regarding proteins that may regulate cisplatin resistance, but
most of this research has not been able to establish if their protein of interest is
sufficient to induce cisplatin resistance. My research builds on the foundations of
these studies establishing potential mechanisms of cisplatin resistance to include
results demonstrating that EDD overexpression is sufficient to promote cisplatin
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resistance, dependent on its ubiquitin ligase activity (Bradley, Zheng et al. 2014).
In addition, my research also confirms that knockdown of EDD increases
cisplatin sensitivity in ovarian cancer. Preliminary results in oral squamous cell
carcinoma cell lines also support this conclusion to expand this knowledge
across distinct types of cancers.
EDD facilitates the DNA damage response that could be occurring in
these cells as a result of cisplatin treatment through the ubiquitination and
designated degradation of Topoisomerase II-binding protein (TopBP1) to prevent
protection of DNA damaged chromosome ends (Honda, Tojo et al. 2002).
Similarly, EDD interacts with CHK2, a checkpoint kinase during DNA damage,
and enables its activating phosphorylation in order to arrest the DNA damaged
cells in mitosis to allow for repair (Henderson, Munoz et al. 2006). Loss of EDD
disrupts cell cycle checkpoints leading to premature, unregulated mitosis and
thus polyploidy (Munoz, Saunders et al. 2007). Recently EDD has also been
shown to cooperate with TRIP12 to maintain RNF168 expression to aid in the
prevention of chromatin ubiquitin spreading to undamaged chromosomes
(Gudjonsson, Altmeyer et al. 2012, Okamoto, Bartocci et al. 2013). While EDD’s
regulation of these proteins was not analyzed in my experiments, my results
demonstrating EDD increases cisplatin resistance further confirms that EDD has
a role in regulating DNA damage response and narrows down EDD’s role as that
of an E3 ubiquitin ligase.
Presently, the only relationship that has been established between EDD
and oral squamous cell carcinoma is the gene amplification of edd. Despite the
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various cellular signaling pathways employed by the oral squamous cell
carcinoma cell lines, my results demonstrate that EDD regulates cellular survival
in a subset of these cell lines. While more experiments are needed to be able to
make direct conclusions, stable knockdown of EDD seems to slow cellular
proliferation due to cisplatin treatment in UM74B cells and knockdown appears to
cause a trend towards increasing cisplatin sensitivity in UM22B cells. The effects
seen in the UM74B cells can be explained based on previous research
describing EDD’s ability to regulate the cell cycle and DNA damage response
(Mansfield, Hersperger et al. 1994, Henderson, Russell et al. 2002, Gupta,
Chakrobarty et al. 2006, Henderson, Munoz et al. 2006, Munoz, Saunders et al.
2007, Ling and Lin 2011, Smits 2012).
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Future Directions
Determine the transcriptional co-factor(s) required for EDD’s
regulation of mcl-1 transcription
Published results from this dissertation identify EDD as a transcriptional
co-activator for the transcription of the anti-apoptotic protein Mcl-1, which
regulates cellular survival in ovarian cancer cell lines (Bradley, Zheng et al.
2014). This effect was determined to be independent of EDD’s ubiquitin ligase
activity. Henderson et al. has also established EDD as a transcriptional coactivator with the progesterone receptor through an interaction in the middle
section of EDD. Transcriptional regulation of Mcl-1 has been highly studied to
demonstrate that Mcl-1 transcription is regulated by several different transcription
factors. In studying the overlap between proteins EDD interacts with and those
that regulate Mcl-1 transcription, β-catenin, E2F1, and GATA-2 were identified. βcatenin and hypoxia-inducible factor 1 α cooperate in prostate cancer cells as a
result of platelet-derived growth factor stimulation to increase mcl-1 transcription
(Iqbal, Zhang et al. 2012). EDD has been identified to ubiquitinate and therefore
stabilize β-catenin to promote its activity (Hay-Koren, Caspi et al. 2011). It stands
to reason that EDD overexpression in cancer could increase ubiquitination of βcatenin, which results in enhanced mcl-1 transcription. The knockdown of EDD
increased protein expression of the E2F transcription factor 1, which can
decrease mcl-1 transcription (Croxton, Ma et al. 2002, Croxton, Ma et al. 2002,
Munoz, Saunders et al. 2007). Thus, overexpression of EDD in cancer could
decrease

E2F1

expression,

allowing
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mcl-1

transcription.

Furthermore,

transcription factor software identified several transcription factors, such as
GATA-2, that regulate mcl-1 transcription (TFSEARCH). As mentioned above,
EDD acts as a transcriptional co-activator for the progesterone receptor, and this
receptor also interacts with GATA-2 in breast cancer cells (Henderson, Russell et
al. 2002, Magklara and Smith 2009). This suggests that EDD could interact as
part of a complex between the progesterone receptor and GATA-2 at the Mcl-1
promoter. Co-immunoprecipitations could be used to identify any of these
transcription factors, or other potential transcription factors, as an interacting
partner of EDD. Additionally, transfection of one of these transcription factors
along with EDD transfection in cells with the mcl-1 promoter-driven luciferase
assay would determine if any of these transcription factors has the potential to
cooperate with EDD in order to increase mcl-1 transcription. In the case of E2F1,
transfection of this transcription factor would decrease mcl-1 transcription, unless
overexpression of EDD has an overwhelming function to decrease E2F1 protein
expression before it can exert its inhibition of mcl-1 transcription. Further analysis
is needed to determine which transcription factors EDD interacts with, either
directly or indirectly as part of a complex, and whether this has an effect on mcl-1
transcription.

Identify novel targets of EDD ubiquitin ligase activity that are
involved in mediating acquired cisplatin resistance
The function of EDD as an E3 ubiquitin ligase is essential for EDD to
mediate cisplatin resistance. While a few substrates of EDD’s ubiquitin ligase
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function have been established, none of these have been established as a direct
link between EDD and cisplatin resistance. EDD may promote substrate
degradation, as with PAIP2, or it may promote protein stabilization, as with βcatenin as a result of substrate ubiquitination (Yoshida, Yoshida et al. 2006, HayKoren, Caspi et al. 2011). In order to determine which substrates are
ubiquitinated by EDD, an inducible stable EDD overexpressing cell line would be
used to overexpress either wild-type EDD or the ubiquitin ligase defective mutant
(Cys2768Ala). In order to create these inducible stable overexpressers, a
piggybac transposon-based expression system will be used. Based on a
publication from James Rini’s lab, the piggyback Rfa plasmid will be used to
encode the EDD gene, a transposase plasmid used for cutting and inserting the
plasmids into the cell genome, and a PB-RB plasmid to encode the reverse
tetracycline-controlled transactivator (rtTA) which includes the tetracycline
repressor and the transactivation domain (Li, Michael et al. 2013). This Tet-on
system will allow for the addition of doxycycline to cells in order to turn on
expression of EDD. Previously, I made these stable cell lines in HEK 293T cells
and Cos-1 cells, but very few of the cells express EDD after selection in both
puromycin (selects for the Rfa-EDD plasmid) and blasticidin (selects for rtTA
expression). To mitigate this problem, I made Rfa plasmids encoding EDD fused
to GFP. This will allow for me to select for cells by florescent automated cell
sorting (FACS) to isolate only those cells which express either GFP wild-type
EDD or GFP Cys2768Ala EDD. Currently, at the time of the writing of this
dissertation, HEK293T and HeLa cells transfected with these plasmids have
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been used to create these inducible stable EDD overexpressing cell lines as
demonstrated in Figure 5.1.
These stable EDD overexpressing cell lines will be used to identify
ubiquitinated substrates through an unbiased proteomics screen. Cells will be
cultured in either light (12C6-Lysine,

12

C6-Arginine) or heavy (13C6-Lysine,

13

C6-

Arginine) SILAC media for 6 passages. For example wild type EDD
overexpressers would be cultured in light media while the ubiquitin defective
mutant EDD overexpressers would be cultured in heavy media. About 6 hours
before collection of the cells, the proteasome inhibitor MG132 will be added to
allow for the accumulation of ubiquitinated proteins. Trypsin digestion will cut
proteins at lysine residues. Immunoprecipitation using an anti-digylcyl lysine
antibody will bind exposed lysine residues on ubiquitin chains on peptides. The
objective is to identify proteins which are ubiquitinated in the wild type EDD
overexpressing cells but not in the Cys2768Ala EDD overexpressing cells.
Multiple replicates would be required for this experiment, also switching the
SILAC media between wild type and mutant EDD to control for differences in
SILAC incorporation, in order to monitor reproducibility of the identified
substrates. The basic experimental outline for this is depicted in Figure 5.2.
Once targets of EDD’s ubiquitin ligase activity are established by mass
spectrometry analysis, these targets would be validated through in vitro
ubiquitination assays. The targets which may play a role in DNA damage
response, cellular survival, and cisplatin sensitivity would be analyzed further
through knockdown and overexpression studies. This would allow for conclusions
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to be drawn about whether a substrate is involved in mediating cisplatin
resistance in ovarian cancer cell lines. It is expected that substrates identified will
play a role in DNA damage repair pathways (such as TOPBP1), apoptotic
pathways, proliferation pathways (such as downstream effectors of ERK or Akt),
transcription (such as β-catenin and the progesterone receptor), translation (such
as PAIP2), and cell cycle control (such as katanin). The results from this would
elucidate the mechanism by which EDD increases cisplatin resistance in cancer,
as examined in aim 2 (Chapter 3).

Figure 5.1.

Figure 5.1. Stable GFP-EDD overexpressing cell lines. HeLa and HEK 293T cell
lines were transfected with either empty Rfa vector control, GFP-Wild type EDD
Rfa, or GFP-Cysteine mutant EDD Rfa vector. These cell line populations were
selected with blasticidin and puromycin. Expression of GFP-EDD was induced
with different concentrations of doxycycline.
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Figure

5.2.

(Adapted

from

http://www.london-research-institute.org.uk/

sites/default/files/protein_analysis_and_proteomics/sailac.bmp)

Cys EDD

Wt EDD

+MG132

Immunoprecipitate
K-G-G on Ubiquitin
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Figure 5.2 Mass spectrometry analysis of ubiquitinated proteins from EDD
overexpressing cell lines. Inducible stable overexpression cell lines, both wild
type EDD and cysteine mutant of EDD, will be grown in SILAC media, either
heavy or light, for 6 passages. MG132 will be added 6 hours before collection.
Cell lysates will be mixed together and ubiquitinated proteins will be
immunoprecipitated using an antibody to the lysine-glycine-glycine remnant on
ubiquitinated proteins after trypsin digestion. Proteins will be separated by SDSPAGE, excised, and sent for mass spectrometry analysis.
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Drug screen for compounds that will enhance cisplatin sensitivity when
EDD is overexpressed
Typically, E3 ubiquitin ligases are not easily targeted by small molecule
inhibitors due to the lack of a defined catalytic pocket. Rather E3 ubiquitin
ligases, such as EDD, rely on protein-protein interactions across multiple
domains on the protein allowing for ubiquitin, an E2 enzyme, and a substrate to
bind to the ligase, often simultaneously. My dissertation research identifies EDD
as an important regulator of cisplatin resistance and cellular survival in ovarian
cancer, and potentially oral squamous cell carcinoma. Figure 3.6 demonstrates
the value of knocking down EDD with DOPC liposome nanoparticles
encapsulating EDD siRNA to increase cisplatin sensitivity in ovarian tumors in
vivo. SiRNAs are much more difficult to use as a therapeutic than small molecule
inhibitors. In order to create a therapy based on this research, a drug screen
could be utilized to identify compounds that could either inhibit EDD, which is
overexpressed in many cancers, or interact with an interacting partner of EDD in
order to prevent EDD’s ability to increase cisplatin resistance. In theory, it is likely
that one of these drugs that enhances cisplatin sensitivity when EDD is
overexpressed would prevent EDD’s ubiquitination of an unknown substrate
since EDD increases cisplatin sensitivity through its ubiquitin ligase activity.
Utilizing inducible GFP-EDD stable overexpressing cell lines, as detailed
above, a combination of cisplatin at a sublethal dose (EC10) and 10 µM of a
compound from the ChemBridge library would be used to test for compounds
that enhance cisplatin induced apoptosis, as illustrated in Figure 5.3. A
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sulforhodamine B cytotoxicity assay (SRB assay) would be used as a highthroughput screen for compounds which increase cisplatin sensitivity in these
EDD overexpressing cells as this assay analyzes cell density based on cellular
protein content as an indirect measure of cellular survival. Approximately 15,000
compounds from the ChemBridge Library would be screened and the top 0.1% of
these drugs along with their chemotypes would be validated. These top
compounds would be tested in a variety of assays (MTT assay, propidium iodide
staining for apoptosis, and colony formation assays) in EDD overexpressing
cells, ovarian cancer cell lines, and primary ascites from MUSC patients, along
with cisplatin treatment to determine which compounds are effective at increasing
cisplatin resistance. A future aim of this project is to analyze the mechanism
which these compounds affect in order to gain a better understanding of the
signaling pathways EDD is affecting to mediate cisplatin resistance. It is possible
that compounds would be identified that do not modify EDD or its cellular
functions, but this approach would still identify compounds which could be useful
in patients that are treated with cisplatin as a first line therapeutic or patients
which are resistant to cisplatin treatment.
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Figure 5.3

Figure 5.3. Drug Screen for compounds that increase cisplatin sensitivity. Wild
type EDD stable overexpressing cells (doxycycline inducible) will be treated with
a suboptimal dose of cisplatin along different compounds from the ChemBridge
library. Controls used will be those cells without EDD overexpression and cells
not treated with cisplatin. A SRB assay will be used to measure cytotoxicity.
Compounds will be validated and modified to find the most suitable compound for
increasing cisplatin sensitivity.
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Analyze alternative responses to stable EDD knockdown in oral
squamous cell carcinoma cell lines
Based on results from aim 3 (Chapter 4), it is apparent that oral squamous
cell carcinoma cell lines vary in their responses when EDD is knocked down with
shRNA. In UM22B cells, as expected based on results seen in ovarian cancer
cell lines, the stable knockdown of EDD sensitizes cells to cisplatin. It should be
noted that this response only occurred at significant levels at moderate doses of
cisplatin treatment (20 µM and 30 µM) as shown in Figure 4.6. Since EDD
mediates cisplatin resistance based on its E3 ubiquitin ligase activity, there may
be something that EDD ubiquitinates which is responsible for maintaining a fine
balance in detecting and/or repairing DNA damage. This unknown ubiquitinated
substrate may be affected when there is a moderate level of DNA damage, but
DNA damage repair is not effective. As proposed above, it would be valuable to
create a better assessment of the pathways and substrates that EDD affects
through the identification of its ubiquitin ligase targets.
On the other hand, UM74B cells do not appear to be sensitive to EDD
knockdown-induced cisplatin sensitivity, although these cells do exhibit slower
rates of proliferation as a result. Based on these results, an analysis of the DNA
damage response pathways and cell cycle control pathways as a result of EDD
stable knockdown with or without cisplatin treatment would be a useful method to
determine the role(s) EDD is playing in this certain oral squamous cell carcinoma
cell line. EDD stable knockdown cell lines could be treated with or without
cisplatin and lysates from these cells could be evaluated by immunoblot for
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altered expression of proteins involved in mediating DNA damage response and
cell cycle control. In addition, these stable knockdown cells could be treated with
other DNA damaging agents such as carboplatin, gemcitabine, etoposide, and
doxorubicin to determine if these chemotherapeutics also decrease the rate of
proliferation in these cells when EDD is lost.
It is crucial based on these unexpected results in different oral squamous
cell carcinoma cell lines that the number of cell lines used in aim 3 be expanded.
This would allow for statistically significant conclusions to be drawn about EDD’s
role in regulating cellular survival and cisplatin resistance in oral squamous cell
carcinoma. Once a role for EDD can be established as regulator of cisplatin
resistance in oral squamous cell carcinoma, stable EDD knockdown cell lines
can be made and tested in nude mouse xenograft models to confirm these
results in vivo (Figure 5.4). It is expected that in vivo results would be similar to
those seen in our ovarian cancer xenograft model in Figure 3.6, which
established that knockdown of EDD increased cisplatin sensitivity.
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Figure 5.4

UM-SCC
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UM-SCC
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saline
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Figure 5.4. In vivo model to test increased cisplatin sensitivity due to EDD stable
knockdown. Nude mice will be injected orthotopically with UM-SCC oral
squamous cell carcinoma cell lines expressing either EDD shRNA or scrambled
control shRNA. Once tumors are established, doxycycline will be added to the
normal mouse chow to induce expression of the shRNA in each tumor. Mice will
then be treated with either saline control or cisplatin and tumor progression will
be measured to determine cisplatin sensitivity.
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Establish the role of EDD phosphorylation
While the focus of this dissertation is the mechanisms by which EDD
affects cellular survival and cisplatin resistance, it is critical to gain a better
understanding of what regulates EDD. One such method of regulation of EDD is
phosphorylation by ERK2 (Eblen, Kumar et al. 2003). Our lab has also published
mass spectrometry results identifying 24 sites of phosphorylation (Bethard,
Zheng et al. 2011). It is currently unknown which kinases, other than ERK2,
contribute to these sites of phosphorylation. Moreover, it is unknown how
phosphorylation of EDD regulates its protein stability, localization, and cellular
functions such as ubiquitin ligase activity and protein-protein interactions. To gain
a better understanding of these effects, the known sites of phosphorylation of
EDD could be mutated to alanine to mimic a lack of phosphorylation at any single
site or a combination of phosphorylation sites. Based on the sites of
phosphorylation, consensus sites of kinases could be analyzed to determine
which kinases may be involved in mediating phosphorylation. An in vitro kinase
assay could then be used to test these kinases to determine if they can
phosphorylate EDD on these sites, but not when these sites are mutated to
alanine. Once potential kinases are established that phosphorylated EDD, kinase
inhibitors could be used to validate phosphorylation by these kinases. These
inhibitors could also establish how phosphorylation of EDD is required to
establish protein-protein interactions. These interactions allow for EDD’s activity
as an ubiquitin ligase and as a transcriptional co-factor, such as for the
transcriptional regulation of mcl-1. It is also possible that a kinase inhibitor could
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be used in conjunction with cisplatin treatment if phosphorylation of EDD by this
kinase is required for ubiquitin ligase activity, thus the kinase inhibitor would
sensitize cells to cisplatin.
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